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▪ ZUSAMMENFASSUNG ▪ 
I 
Zusammenfassung 
Körperliche Aktivität löst eine akute Stressreaktion aus, welche starke 
Veränderungen von physiologischen Parameter mit sich bringt. Diese akuten 
Veränderungen verursachen systemische Anpassungen, die langfristig die 
körperliche und geistige Gesundheit fördern. Die zugrundeliegenden 
Mechanismen sind jedoch noch nicht völlig geklärt. Extrazelluläre Vesikel 
(EVs) sind von Zellen abgegebene membranumschlossene Einheiten, die 
bioaktives Material transportieren und als Vermittler der Zell-zu-Zell-
Kommunikation zwischen verschiedenen Organen und Geweben fungieren. 
Die Menge an EVs in der Zirkulation nimmt in Folge verschiedener körperlicher 
Betätigungen zu und es wird spekuliert, dass EVs an physiologischen 
Anpassungsprozessen beteiligt sind, welche durch regelmäßige körperliche 
Bewegung ausgelöst werden. Das Wissen über die Dynamik, den Ursprung 
und die Zusammensetzung von EVs, die während und nach dem Sport im Blut 
zu finden sind (bezeichnet als „ExerVs“), ist jedoch begrenzt. Zudem stellt die 
erschwerte Isolation von EVs aus Blutplasma eine Hürde für die 
Charakterisierung von ExerVs dar. 
Hier wurde eine detaillierte Analyse verschiedener ExerV-Subklassen mit dem 
Ziel einer genauen Beschreibung ihrer Freisetzungskinetik und ihrer zellulären 
Herkunft durchgeführt. Dafür wurden 21 gesunde männliche Athleten einem 
stufenweisen Ausbelastungstest auf dem Fahrradergometer unterzogen. Die 
EV-Isolierung mittels Größenausschlusschromatographie (englisch „size 
exclusion chromatography“ = SEC), Immunaffinitäts-Isolation sowie die 
Kombination von SEC mit Dichtegradientenzentrifugation führten zur 
Anreicherung von EVs aus Blutplasma. Semi-quantitative Analysen der ExerV-
Dynamik in SEC-EVs und Immunaffinität-isolierten EVs ergaben Anstiege über 
den Verlauf der Belastung. Die Phänotypisierung von ExerVs mittels zweier 
Multiplex-Analysemethoden direkt im Blutplasma oder mit isolierten SEC-EVs, 
CD9+EVs, CD63+EVs und CD81+EVs ergab eine Reihe an zellulären 
Markerproteinen, die auf ExerVs zu finden sind. Die Ergebnisse deuten darauf 
hin, dass ExerVs von Leukozyten, einschließlich Lymphozyten (CD4+EVs, 
CD8+EVs), Monozyten (CD14+EVs) und antigenpräsentierenden Zellen 
(MHCI+EVs, MHCII+EVs), sowie Endothelzellen (CD105+EVs, CD146+EVs) 
und Thrombozyten (CD41b+EVs, CD62P+EVs), freigesetzt werden. Die 
massive Beeinträchtigung der Analyse des Proteoms von verschieden 
isolierten ExerVs, sowie der Nanopartikel-Tracking-Analyse und der 
bildgebenden Durchflusszytometrie verdeutlicht die Notwendigkeit einer 
weiteren Verbesserung der EV-Reinheit, um tiefere Einblicke in die 
tatsächlichen Konzentrationen und die Zusammensetzung von ExerVs zu 
erhalten. 
Schlussendlich kann festgehalten werden, dass verschiedene Zelltypen des 
Kreislaufsystems während physischer Belastung dazu beitragen, dass 
extrazelluläre Vesikel ins Blut abgegeben werden. Diese heterogenen ExerV 
Spezies könnten an Signalprozessen beteiligt sein, die in Zusammenhang mit 
Koagulation, Endothelfunktion und Inflammation stehen.
▪ SUMMARY ▪ 
III 
Summary 
Physical exercise induces acute physiological changes leading to massively 
enhanced cross-talk between cells, organs, and tissues. These acute 
alterations cause systemic adaptations which promote physical and mental 
health on a long-term. Though, the molecular basis underlying these bodily 
adaptations remains elusive. Extracellular vesicles (EVs) are cell-derived 
membranous entities which transport bioactive material and function as 
mediators of cell-cell-communication between several organs and tissues. EVs 
in the circulation increase upon diverse exercise interventions and are 
speculated to be involved in the physiological adaptation processes induced 
by regular physical exercise. However, knowledge on the dynamics, the origin, 
and the composition of EVs present in blood during and after exercise (ExerVs) 
is poor. In addition, the difficulties in EV-isolation from blood plasma represents 
a hurdle for the characterization of ExerVs. 
Here, a detailed analysis of different ExerV subclasses to define their release 
kinetics and their origin was performed in an incremental cycling exercise 
setting involving 21 healthy male athletes. EV isolation via size exclusion 
chromatography (SEC), immuno-affinity capture as well as combination of 
SEC with density gradient centrifugation lead to enrichment of EVs from 
human plasma samples. Semi-quantitative analyses of ExerV dynamics in 
SEC-EVs and immuno-affinity captured EVs revealed elevations in a load-
response related fashion. Phenotyping of ExerVs using two multiplexed 
analysis approaches directly in blood plasma or isolated SEC-EVs, CD9+EVs, 
CD63+EVs, and CD81+EVs revealed a panel of cellular marker proteins 
present on ExerVs. The results indicate that ExerVs originate from leukocytes, 
including lymphocytes (CD4+EVs, CD8+EVs), monocytes (CD14+EVs) and 
antigen presenting cells (MHCI+EVs, MHCII+EVs), as well as endothelial cells 
(CD105+EVs, CD146+EVs), and platelets (CD41b+EVs, CD62P+EVs). 
Impaired downstream analysis of proteomic content, nanoparticle tracking 
analysis, and imaging flow cytometry analysis of differentially isolated ExerVs 
demonstrated the need for further improvement of EV purity to gain deeper 
insights on actual concentrations and the composition of ExerVs. 
Conclusively, various cell types of the circulatory system contribute to the 
exercise-triggered release of extracellular vesicles into the blood stream. This 
heterogeneous pool of ExerVs may be involved in signaling processes 
associated with coagulation, endothelial function and inflammation. 
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1 Introduction 
1.1 Physical exercise 
Physical exercise induces an acute stress situation in the body which 
immediately persuades several organs and cell populations to maintain whole-
body homeostasis. In order to supply the tissues with an increasing amount of 
nutrients and oxygen, the respiratory, the cardiovascular as well as the 
neuromuscular systems are activated. Consequently, enhanced shear forces, 
oxidative stress and inflammatory reactions can be observed. When physical 
activity is performed under controlled conditions these bodily alterations are 
beneficial for health and exercise has become an important instrument in 
disease prevention, diagnostics and rehabilitation (Zierath et al., 2015), 
(fig. 1.1).  
1.1.1 Health benefits of physical exercise 
Regular physical activity and exercise leads to the primary and secondary 
prevention of several chronic diseases and is linked to reduced risk of 
premature death. A graded linear relationship between the volume of physical 
activity and health status seems to exist. As reviewed by Warburton et al. 
(2006), increased levels of physical activity reduce the risk for cardiovascular 
diseases and mortality. Physically active people are less likely to develop type 
2 diabetes and exercise interventions improve glucose homeostasis which is 
associated with an improved course of disease (Warburton et al., 2006). 
Likewise, the clinical risk factors of the metabolic syndrome are reduced, 
including abdominal obesity, hypertension, elevated serum triglycerides, low 
serum high-density lipoprotein (HDL) and insulin resistance (Pitsavos et al., 
2006). Furthermore, the incidence of specific cancers, particularly colon and 
breast cancer, is reduced in persons that are routinely physically active. In the 
secondary prevention, regular physical exercise improves health status of 
cancer patients and reduces their relative risk for death. Additionally, physical 
exercise affects bone mineral density, reducing the incidence of osteoporosis. 
Subsequently, the risk of fractures is reduced, especially in elderly people 
(Warburton et al., 2006). 
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Next to the physiological effects, exercise is known to have cognitive benefits 
in the general population including neuroprotection. Exercise is associated 
with enhanced neurogenesis and synaptic plasticity (Lourenco et al., 2019; van 
Praag, 2008). In the aging process, this leads to a reduced decline in age-
related impairments. Active persons are less prone to develop Alzheimer’s as 
well as Parkinson’s diseases and disease progression is reduced in exercising 
patients (Paillard et al., 2015). In addition, exercise reduces the cognitive 
decline (Sun et al., 2018) and improves quality of life in depressive patients 
(Blumenthal et al., 2007; Haller, Lorenz, et al., 2018). Similarly, overall 
resilience to stressors seems to be improved in trained persons (Tsatsoulis et 
al., 2006). 
Thus, adaptive mechanisms induced by exercise seem to exhibit an overall 
positive effect on physical and neuronal health. 
 
Figure 1.1: Systemic benefits of exercise. Exercise exhibits several physiologic 
changes which promote inter-organ cross-talk leading to beneficial systemic 
adaptations. 
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1.1.2 Physiological changes of the body in response to exercise 
Catecholamines and glucocorticoids 
Activation of the hypothalamic pituitary adrenal (HPA) axis, which is stimulated 
by neuronal and circulating homeostatic signals as well as inflammatory 
mediators, causes catecholamine and glucocorticoid release during exercise 
(Duclos et al., 2016). The catecholamines adrenaline and noradrenaline are 
released within seconds and the concentrations increase with power and 
duration of physical activity (Zouhal et al., 2008). The glucocorticoid cortisol 
can be found in the circulation after few minutes during acute exercise and 
remains elevated for up to two hours (Duclos et al., 2016). Signaling processes 
involving these circulating stress hormones trigger an increased mobilization 
of metabolic substrates (gluconeogenesis, lipolysis, proteolysis) and their rapid 
delivery to muscle cells by an enhanced cardiovascular tone (Sapolsky et al., 
2000; Zouhal et al., 2008). Interestingly, trained subjects, in contrast to 
untrained persons, are capable of sequential HPA activation induced by 
exercise. Alterations of the glucocorticoid receptor representation in the brain 
may be a major adaptation related to the regulation of the circulating cortisol 
levels in active persons (Duclos et al., 2016). Also, catecholamine secretion 
seems to be promoted in trained versus sedentary humans and rats (Kjaer, 
1998; Schmidt et al., 1992). Physiologic adaptations underlying these 
observations may involve increased adrenal medulla volume, adrenergic 
receptor density or sensitivity as well as genetic predisposition (Zouhal et al., 
2008). 
Shear stress 
Increasing heart rate and blood pressure lead to highly elevated levels of shear 
stress under exercise conditions. As a result, endothelial cells release 
increasing levels of nitric oxide (NO) leading to flow-mediated dilatation 
(Vanhoutte et al., 2017). This is, among other processes, mediated by 
activation of the NO synthase (eNOS). Under physiological conditions, NO 
release is important for proper endothelial functions to prevent clot formation 
and abnormal vasoconstriction. Aggregated platelets release serotonin and 
adenosine diphosphate which persuade the endothelium to release NO. This 
leads to the constriction of vascular smooth muscle cells as well as inhibition 
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of coagulation and a subsequent clot formation process. Endothelial 
dysfunction due to disrupted vessel walls or decreased NO production leads 
to higher susceptibility to atherosclerosis, clot formation and ischemic insults 
(Vanhoutte et al., 2017). Chronic exposure to elevated levels of shear stress 
induced by regular training leads to an upregulation of eNOS in endothelial 
cells and, thus, higher levels of NO are released upon stimulation (Rizzo et al., 
1998; Woodman et al., 2005). Finally, the increase of intraluminal shear forces 
is considered a major stimulus for the exercise-triggered enhancement of 
vascular function and reduction of the risk for cardiovascular diseases 
development. 
Oxidative stress 
Enhanced metabolic turnover during physical exercise results in incomplete 
oxidative phosphorylation. Thus, liberation of free radicals leads to a strong 
increase of reactive oxygen species (ROS) in blood. After prolonged or 
excessive exercise, the resulting oxidative stress exhibits harmful impact 
especially on muscle cells (Powers et al., 2011). However, in trained 
individuals elevated superoxide dismutase (SOD) concentrations as well as 
altered redox signaling mediated by the transcription factor nuclear factor 
erythroid 2-related factor or beneficial oxidation of involved proteins’ cysteine 
residues can be observed (He et al., 2016). This indicates that, when 
performed under controlled conditions, exercise leads to adaptive responses 
of the antioxidant defense system. 
Immune reactions 
Exercise induces an inflammatory reaction of the body with each individual 
bout of exercise. This is reflected by increased levels of cytokines and 
leukocytes in the blood. Several lymphocyte subpopulations [cluster of 
differentiation (CD)4+ T cells, CD8+ T cells, CD16+ natural killer (NK) cells 
CD56+ NK cells, and CD19+ B cells] are recruited to the circulation, while the 
ratio of CD4+ to CD8+ T cells declines due to a higher increase in CD8+ T cells 
(Pedersen et al., 2000). Early during exercise interleukin (IL)-6 concentrations 
in the circulation rise up to 100-fold and decline to baseline thereafter (Walsh 
et al., 2011). With contradicting results, other cytokines like tumor necrosis 
▪ INTRODUCTION▪ 
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factor α and IL-1β, which strongly increase during inflammatory reactions in 
several diseases, were found either to increase or remain at baseline 
depending on exercise duration and intention (Pedersen et al., 2000). This 
possibly indicates that induction of a similar inflammatory reaction as in 
disease states is only found under intense exercise conditions like marathon 
running (Pedersen et al., 2008). After exercise, an anti-inflammatory reaction 
is mediated by an elevated level of IL-6 propagating IL-10 and IL-1 receptor 
antagonist release from peripheral blood mononuclear cells (Steensberg et al., 
2003). Also, long-term anti-inflammatory effects may be attributed to IL-6, IL-
15 and follistatin-related protein 1 release during exercise which mediates 
improvement of cardiovascular health (Pedersen et al., 2012). In line with this, 
a reduction of circulating inflammatory markers can be observed due to regular 
physical activity in combination with reduced energy intake (Petersen et al., 
2005). In pathophysiological situations, like rheumatoid arthritis, systemic 
sclerosis, idiopathic inflammatory myopathies, and systemic lupus 
erythematosus, exercise also exhibits anti-inflammatory effects (Benatti et al., 
2015). Taken together, the pro- and anti-inflammatory reactions observed 
during and after acute bouts of physical exercise may be responsible for 
beneficial log-term immune adaptations. 
In conclusion, physical exercise induces broad systemic changes which on the 
long-term lead to a wide range of beneficial properties. Multiple complex 
adaptational processes occur in the circulation and the embedding tissues 
including muscle and brain. Still, the exact molecular mechanisms responsible 
for these positive effects remain incompletely understood. 
1.1.3 Evaluation of physical exertion 
In order to study the molecular basis including adaptations to regular physical 
exercise, the precise evaluation of exercise performance is crucial. The 
implication of various exercise settings enables induction of acute stress 
situations in healthy persons or disease patients and a subsequent analysis of 
the body’s physiological response. To characterize physical fitness and acute 
physical exertion, several parameters like heart rate, blood lactate levels and 
oxygen consumption can be assessed. To this end, incremental exercise tests 
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with increasing exercise intensities are frequently applied e.g. at a treadmill or 
a cycling ergometer. 
The heart rate can easily be determined and stated as percentage of maximum 
heart rate to evaluate individual exertion. Subjective estimation of perceived 
exertion of the participants can be determined with the Borg scale (6 = no 
exertion; 20 = very, very hard) (Borg, 1982). The maximal oxygen consumption 
(VO2max) is an important determinant for the aerobic capacity of a person 
(Howley et al., 1995; Taylor et al., 1955). It is defined as the maximum amount 
of oxygen per minute that can be taken up, transported and metabolized by 
the exercising muscles. Oxygen consumption and ventilatory thresholds can 
be assessed by applying spiroergometric analysis (Svedahl et al., 2003). Also 
in spiroergometric analysis, the respiratory exchange ratio (RER) is estimated 
by the division of the produced carbon dioxide (CO2) by the consumed O2. The 
RER can be used as an approximation for the respiratory quotient (RQ). The 
RQ allows evaluation of the nutrients which are mainly used for energy 
production since different amounts of oxygen are needed for the final oxidation 
of carbohydrate (RQ = 1.0), fat (RQ = 0.7), and protein (RQ = 0.82). 
Consequently, an RQ of 0.9 indicates the approaching switch from fatty acid 
metabolism to glucose metabolism due to increasing exertion during exercise 
(Issekutz et al., 1961; Wasserman et al., 1973). Lactate, the end product of the 
anaerobic glycolysis, is formed in muscle tissue and accumulates in the blood 
which similarly reflects the increasing demands for energy during strenuous 
exercise. Measurement of the blood lactate concentration is used for the 
estimation of the individual anaerobic threshold (IAT) which can be defined by 
multiple threshold concepts (Dickhuth et al., 1999; Faude et al., 2009; Mader 
et al., 1986; Stegmann et al., 1981). As a novel molecular marker in exercise 
physiology, circulating cell-free DNA (cfDNA) has gained increasing attention 
in the last years. It was demonstrated that cfDNA concentrations are 
increasing in various exercise settings and might provide more detailed 
knowledge on the molecular mechanisms activated during physical exercise 
(Beiter et al., 2011; Breitbach et al., 2012). Development of highly sensitive 
detection methods (Breitbach, Sterzing, et al., 2014; Breitbach, Tug, et al., 
2014) enables routine analysis of cfDNA in exercise studies (Breitbach, 
Sterzing, et al., 2014; Haller, Helmig, et al., 2018; Tug et al., 2017). 
▪ INTRODUCTION▪ 
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Conclusively, many different methods for the estimation of an athlete’s fitness 
level and the characterization of an acute exercise intervention exist. However, 
controversial discussion is ongoing about different diagnostic concepts and 
new methods are developed for performance diagnostics also in 
pathophysiological settings. Controlled exercise settings are most reliable to 
study intercellular signaling and adaptational processes in response to 
physical activity. 
1.2 Extracellular vesicles – mediators of cell-cell communication 
In the last decades extracellular vesicles (EVs) have evolved as important 
players of cell-cell communication. Upon diverse stimuli EVs are released in a 
variety of body fluids including blood plasma, urine, lymph and cerebrospinal 
fluid (Yanez-Mo et al., 2015). They compose of a phospholipid bilayer 
membrane encapsulating proteins, lipids, and several nucleic acid species, 
which differ dependent on their parent cells, environmental factors and certain 
stimuli (Raposo et al., 2013). Furthermore, an increasing number of studies 
evolved which show the transport of bioactive material to recipient cells. This 
makes them versatile entities in various physiologic and pathophysiologic 
processes (Raposo et al., 2013; van Niel et al., 2018; Yanez-Mo et al., 2015). 
1.2.1 EV biogenesis and fate 
Initially, vesicles found in the extracellular space were assumed to be cellular 
waste products (Johnstone et al., 1987; Wolf, 1967). However, defined EV 
release mechanisms of different subcellular origins were discovered in the last 
years. Despite today a highly diverse nomenclature exists, three main types of 
EVs can be differentiated: a) small exosomes originating from the endosomal 
machinery, b) microvesicles (MVs) directly shedding from the plasma 
membrane and c) apoptotic bodies formed as large vesicles during the process 
of apoptosis, (Colombo et al., 2014; van Niel et al., 2018), (fig. 1.2). Exosomes, 
due to their endosomal origin, are around 50-150 nm in size, MVs and 
apoptotic bodies vary in diameter of 50-1000 nm with apoptotic bodies also 
found larger than 1 µm (Jeppesen et al., 2019; van Niel et al., 2018). While the 
process of apoptosis and subsequent formation of apoptotic bodies is known 
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for long time (Elmore, 2007), the active secretion of exosomes and MVs is 
recently under intense investigation.  
 
Figure 1.2: EV formation and release. EVs can be classified as exosomes released 
from multivesicular bodies (MVBs), microvesicles blebbing from the plasma 
membrane, and apoptotic bodies formed during apoptotic processes. Adapted from 
(Karpman et al., 2017). 
 
Exosomes are formed as intraluminal vesicles (ILVs) within the endosomal 
machinery and actively released upon fusion of multivesicular bodies (MVBs) 
with the cellular membrane. ILV-formation by inward-budding of the early 
endosomal membrane is driven by different endosomal sorting mechanisms 
(Colombo et al., 2014; van Niel et al., 2018), (fig. 1.3 lower part). The 
endosomal sorting complex required for transport (ESCRT)-dependent 
machinery requires a complex interplay of around 30 proteins (Hanson et al., 
2012). ESCRT-0 and ESCRT-I complexes are responsible for the assembly of 
ubiquitinated transmembrane cargoes on microdomains of the MVB 
membrane. HRS (hepatocyte growth factor-regulated tyrosine kinase 
substrate) of ESCRT-0 binds to tumor susceptibility gene 101 protein 
(TSG101) of ESCRT-I which further promotes the recruitment of ESCRT-III by 
ESCRT-II or apoptosis-linked gene-2-interacting protein (Alix). This finally 
leads to vesicle budding into the lumen of the MVBs. Moreover, Syndecan and 
Syntenin are important players of these ESCRT-mediated processes (Baietti 
et al., 2012). However, also ESCRT-independent ILV formation can be 
observed. Local enrichment of ceramide by hydrolysis of sphingomyelin on 
membrane subdomains can lead to membrane inward-budding (Goni et al., 
2009; Trajkovic et al., 2008). Additionally, tetraspanins which consist of four 
transmembrane domains cluster in high concentrations on the MVB membrane 
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(Charrin et al., 2014). The tetraspanins CD9, CD63 and CD81 were shown to 
be involved in direct sorting of cargo to these so formed microdomains 
(Buschow et al., 2009). Inward budding and scission of the microdomains as 
ILVs are further triggered by the tetraspanin family members without the 
presence of the ESCRT complexes (Charrin et al., 2014; van Niel et al., 2011). 
MVB transport to the plasma membrane is mediated by Rab (ras-related in 
brain) GTPases like Rab11, Rab27, and Rab35 (Stenmark, 2009). 
Subsequently, fusion of the MVB membrane with the cellular membrane is 
driven by SNARE (soluble N-ethylmaleimide-sensitive-factor attachment 
receptor) proteins and synaptogamin family members resulting in exosome 
secretion to the extracellular space (Jahn et al., 2006).  
 
Figure 1.3: Distinct formation and release mechanisms of exosomes and MVs. 
Upper part: Cargo clustering in tetraspanin-rich domains is followed by cytoplasmic 
sorting and lipid translocation. Finally, lipid flipping initiates budding of the ceramide 
rich domain and shedding of MVs. Lower part: ESCRT-dependent (right) 
and -independent (left) cytoplasmic sorting of cargo in clusters is likewise followed by 
bending of the ceramide-rich domain and ILV scission into the MVB lumen. ILVs will 
be released to the extracellular space as exosomes after fusion of the MVB 
membrane with the cellular membrane. Adapted from (van Niel et al., 2018). 
MV secretion directly from the cellular membrane shows certain similarities 
with exosome generation (van Niel et al., 2018), (fig. 1.3 upper part). Also prior 
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to MV release, membrane domains are formed involving tetraspanins for cargo 
clustering. Subsequently, restructuring of the cytoskeleton and membrane 
bending is required for MV blebbing. This is induced by Ca2+-dependent 
pathways causing the exposition of phosphatidylserine to the cell surface 
where it generates a ceramide-rich membrane (Bianco et al., 2009; Piccin et 
al., 2007). Additionally, interaction of GTPases of the RHO (Ras homologue)-
family and ROCK (RHO-associated protein kinase) with the cytoskeleton 
mediates MV release (McConnell et al., 2009). However, also proteins 
involved in exosome formation including TSG101, components of the ESCRT 
machinery, and Rab proteins were shown to act as mediators of MV shedding 
(Colombo et al., 2014).  
After liberation to the extracellular space, EVs may target recipient cells and 
either function as signaling molecules themselves or deliver their cargo. 
Though EV targeting to recipient cells remains incompletely understood, it is 
likely dependent on specific adhesion molecules embedded in their 
membranes (Mathieu et al., 2019; van Niel et al., 2018). For instance, 
tetraspanins on EVs interact with intercellular adhesion molecules (ICAMs) at 
the membrane of acceptor cells (Morelli et al., 2004). But also integrins, lipids, 
lectins, heparan sulfate proteoglycans and extracellular matrix components 
are involved in EV-target cell recognition (van Niel et al., 2018). EV uptake can 
then be mediated by clathrin-dependent or -independent endocytosis as well 
as through endocytosis via caveolae and lipid rafts or by direct membrane 
fusion (Mathieu et al., 2019; van Niel et al., 2018). Once taken up by the cell, 
EVs are shuttled through the endosomal pathways and their cargo can be 
released into the cytoplasm where it may induce phenotypic changes. Though 
the actual mechanisms of EV cargo retrieval are poorly understood, numerous 
studies emerged (reviewed in Yanez-Mo et al., 2015) demonstrating the active 
release of EVs from one cell followed by uptake into a recipient cell and 
functional signaling of selected encapsulated cargo (Yanez-Mo et al., 2015). 
1.2.2 EV-mediated intercellular signaling in the circulation 
The capability of transporting bioactive material makes EVs interesting 
mediators of intercellular signaling and tissue homeostasis. EVs in blood 
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comprise a heterogeneous mixture of vesicles derived from platelets, red blood 
cells (RBCs; together > 50 %) (Arraud et al., 2014), and other blood cells 
including NK cells, dendritic cells (DC), monocytes and neutrophils as well as 
from cells of the surrounding tissues and organs (Yanez-Mo et al., 2015). 
Reports on blood EV numbers are diverse, ranging from 200 to 109/µl plasma 
highly depending on the method of examination (Dragovic et al., 2011; Shet et 
al., 2003), but more sophisticated analysis indicates an EV concentration of 
around 50,000/µl plasma (Arraud et al., 2014). Their presence in the circulation 
is restricted to few minutes or hours before they reach their targets (Rand et 
al., 2006; Takahashi et al., 2013; Willekens et al., 2005). Subsequently, EVs 
are taken up from their recipient cells and their cargo can be functionally 
retrieved. 
EVs in blood homeostasis 
Multiple EV subtypes in the circulation contribute to the maintenance of blood 
homeostasis via contribution to coagulative processes. Platelets release 
several EV subtypes triggered by diverse platelet activation routes (Heijnen et 
al., 1999; van der Pol et al., 2012). Large phosphatidylserine- or tissue factor 
(TF)-positive platelet-EVs induce thrombin generation (Biro et al., 2003; 
Tripisciano et al., 2017) but also small EVs or specifically exosomes may be 
responsible for pro-coagulative reactions (Berckmans et al., 2001; Thery et al., 
2009; van der Pol et al., 2012). However, also EVs from other cellular sources 
bear pro-coagulative capacity. For example, EVs originating from polymorph 
nuclear neutrophils were demonstrated to trigger TF expression in endothelial 
cells (Mesri et al., 1999). Furthermore, EVs derived from monocytes were 
reported to be TF-positive and to promote coagulation upon binding to P-
selectin-positive platelets (Del Conde et al., 2005). Interestingly, also anti-
coagulant (Heijnen et al., 1999; Steppich et al., 2005) and fibrinolytic activity 
(Lacroix et al., 2012) can be attributed to EVs. This indicates that EVs may be 
part of a sensitive signaling machinery for precise homeostatic maintenance 
under physiologic conditions (Melki et al., 2017; Tans et al., 1991). Intriguingly, 
coagulation and thrombus formation are increased under several pathologic 
conditions like cancer, cardiovascular disease and rheumatoid diseases (Melki 
et al., 2017; Yanez-Mo et al., 2015). The described clinical conditions lead to 
elevated levels of circulating platelets and monocytes and increased pro-
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coagulant activity of endothelial cells. These findings are accompanied by 
enhanced generation of pro-coagulant EVs, as well as increased risk for clot 
formation and thrombosis. 
EVs in angiogenesis and vessel sprouting 
EVs were reported to contribute to angiogenic signaling under healthy and 
pathologic conditions. Endothelial cell-derived EVs which contain matrix 
metalloproteinase proteins (MMP2 and MMP9) induced matrix degradation 
and therefore promoted blood vessel formation in vitro (Taraboletti et al., 
2002). Moreover, platelet-derived EVs are described to promote proliferation 
and formation of vessel-like structures in endothelial cell culture as well as 
vessel-sprouting and revascularization of rat heart muscle after ischemia (Brill 
et al., 2005; Kim et al., 2004). Transport of growth factors like vascular 
endothelial growth factor, basic fibroblast growth factor and platelet derived 
growth factor seems to be involved in these pro-angiogenic signaling 
processes (Brill et al., 2005). Also, transfer of RNA species from mononuclear 
cells to endothelial cells via EVs with pro-angiogenic effects was demonstrated 
in vivo and in vitro (Deregibus et al., 2007). Furthermore, mesenchymal stem 
cell (MSC)-derived EVs induced vascular adaptations in endothelial cells 
under hypoxic conditions (Salomon et al., 2013). Accordingly, also tumor 
angiogenesis is supported by EVs originating from cancer and other cells via 
induction of growth factor or MMP expression (Janowska-Wieczorek et al., 
2005; Skog et al., 2008). Next to pro-angiogenic signaling, also anti-angiogenic 
effects were reported for endothelial cell- and lymphocyte-derived EVs. These 
were reflected by enhanced ROS production and decreased NO release of 
endothelial cells upon stimulation with EVs (Mostefai et al., 2008; C. Yang et 
al., 2008). Conclusively, EVs exhibit modulating effects on angiogenic 
signaling, including induction and inhibition of vessel sprouting and tumor 
growth. 
EVs as mediators of immune signaling 
EVs play a versatile role in innate as well as acquired immunity by mediating 
inflammatory signaling. NK cells, monocytes/macrophages, and 
polymorphnuclear neutrophils (PMN), the first line of immune defense, release 
EVs under various conditions. Propagating pro- or anti-inflammatory reactions, 
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these EVs carry cytokines like IL-1β or IL-6, pattern recognition receptors like 
TLRs (toll-like receptors) as well as pro-inflammatory ligands like HMGB1 (high 
mobility group box 1), miRNAs, DNA, and PAMPs (pathogen-associated 
molecular patterns) (Yanez-Mo et al., 2015). For example, macrophage-
derived EVs encapsulating miR-223 were potent to stimulate differentiation of 
monocytes to macrophages (Ismail et al., 2013). Also, EVs liberated by NK 
cells were Fas ligand- and perforin-positive and displayed cytotoxic activity 
against tumor cells as well as activated immune cells (Fais, 2013; Lugini et al., 
2012). As part of the acquired immune response, EVs are involved in antigen 
processing and presentation. Antigen presenting (AP) cells can be affected by 
the capture of EVs carrying antigens from originating cells which experienced 
an inflammatory stimulus (van der Pol et al., 2012). This may lead to 
enhancement or reduction of subsequent T cell stimulation processes. 
Furthermore, AP cells were demonstrated to liberate EVs carrying major 
histocompatibility complex (MHC) I or MHCII and co-stimulatory molecules, 
thus, utilizing EVs for antigen presentation. For example, different 
subpopulations of dendritic cell-derived MHCII+EVs stimulated the activation 
and proliferation of T cells (Tkach et al., 2017). Interestingly, DC-EV 
subclasses may induce divergent reactions in T cells (Th1- or Th2-associated), 
dependent on DC maturation state. Finally, the involvement of EVs in the 
described inflammatory processes is found under various pathologic 
conditions like infection, sepsis, rheumatoid arthritis, atherosclerosis, 
autoimmune diseases, and cancer (Yanez-Mo et al., 2015).  
Organ cross-talk via EVs 
Several lines of evidence demonstrate that EVs in the circulation reach tissues 
and organs to mediate organ-cross talk. For instance, accumulating data 
suggests that EVs are capable of crossing the blood-brain-barrier (BBB) and 
contribute to signaling processes between the periphery and neuronal tissue. 
Under physiologic conditions, the central nervous system is protected from 
insult from the circulation by the BBB as well as the blood-cerebrospinal fluid-
barrier (BCSFB) which facilitate proper exchange of substances between 
blood and brain. Recently, it was demonstrated that EVs presumably 
originating from the hematopoietic lineage can cross the BBB and transfer 
bioactive cargo to recipient neuronal cells which seems to be enhanced under 
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inflammatory conditions (Chen et al., 2016; M. K. Qu et al., 2018; Ridder et al., 
2014). Likewise, EV-mediated cell-cell communication at the BCSFB appears 
to be part of the immune reaction in neuronal tissue (Balusu et al., 2016). 
Additionally, the use of EVs to shuttle therapeutics from blood to brain (Kalani 
et al., 2014; M. Qu et al., 2018; T. Yang et al., 2015) as well as the ability of 
MSC-derived EVs to cross the BBB and their positive influence on several 
brain disease (Morales-Prieto et al., 2018) have gained increasing attention. 
However, while the capability of EVs to cross the BBB is widely accepted, the 
underlying molecular mechanisms are barely understood. Taken together, EVs 
can be regarded as important mediators of the exchange between tissues and 
organs, e.g. from periphery to brain, which makes them exciting targets for 
diagnostic and treatment of diseases. 
1.3 Challenges in the isolation and characterization of plasma 
EVs 
The heterogeneity of EV populations and other bioactive components found in 
the circulation faces the EV research with numerous challenges. Next to the 
different EV subclasses, also lipoprotein species in high concentrations, 
plasma proteins, including albumin, clotting factors, immunoglobulins, and 
further structures are present in blood (fig. 1.4). 
The most frequently used EV isolation techniques from blood plasma or serum 
are differential ultracentrifugation (UC) and commercial precipitation-based 
methods (EV-Track knowledgebase; (Van Deun et al., 2017)). However, it was 
demonstrated that application of UC or EV precipitation results in low purity 
EVs with high amounts of co-isolated plasma proteins and lipoproteins (van 
der Pol et al., 2014) and may lead to the formation of aggregates (Linares et 
al., 2015). As a result, multiple different EV purification techniques emerged 
over the last couple of years trying to separate EVs from these main 
contaminants (Li et al., 2017; Monguio-Tortajada et al., 2019). Lipoproteins, 
which are found in concentrations of 1016/ml in plasma, share either the size 
[chylomicrons, very low-density lipoprotein (VLDL)] or the density (HDL) with 
EVs (Simonsen, 2017), (fig. 1.4). Size exclusion chromatography (SEC) can 
be used to separate the majority of plasma proteins and lipoproteins (Boing et 
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al., 2014; Lobb et al., 2015; Welton et al., 2015) from EVs which can be 
subjected to various downstream analysis methods. However, the remaining 
contaminants still hamper the subsequent use of EV eluates for sensitive 
downstream analysis like RNA-sequencing (RNA-seq) or proteome analysis. 
It turned out that combination of different EV strategies, especially with density 
gradient centrifugation, leads to high-purity EVs (Jeppesen et al., 2019; Karimi 
et al., 2018; Onodi et al., 2018). Though, these approaches need an elevated 
sample input, are highly laborious, and show a low recovery, which hampers 
their usage in clinical settings. Immuno-affinity (IA) isolation including magnetic 
separation of captured EVs from plasma components offers a quick possibility 
to enrich for specific EV populations (Greening et al., 2015; Kowal et al., 2016; 
Nakai et al., 2016). However, applying IA isolation introduces a selection bias 
for the chosen EV-associated protein. Finally, more and more innovative 
isolation strategies appear with the aim to overcome the named disadvantages 
of the frequently used purification strategies (Bryl-Gorecka et al., 2018; Li et 
al., 2017; Sitar et al., 2015).  
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Figure 1.4: EVs and non-EVs in the circulation. Size (a) and density (b) of different 
EV-subsets and other circulating particles. HDL = high-density lipoprotein, LDL = low-
density lipoprotein, IDL = intermediate-dense lipoprotein, VLDL = very-low-density 
lipoprotein. Adapted from (Mathieu et al., 2019). 
Given the complex composition of the plasma EV-pool and the limitations in 
EV purification, EV characterization is similarly challenging as EV isolation. 
Western blotting (WB), single particle tracking, and electron microscopy (EM) 
are the most frequently used methods to characterize EV size and composition 
(Gardiner et al., 2016). Due to the lack of exclusive marker proteins and 
purification strategies for the EV subclasses (exosomes and MVs) the primary 
criteria to differentiate EVs in blood is size, preferably speaking of small and 
large EVs (Jeppesen et al., 2019; Kowal et al., 2016; Tkach et al., 2017). EM, 
specially coupled with immuno-gold labeling, is the gold standard of basic EV 
characterization (Thery et al., 2018; van der Pol et al., 2014). However, this 
technique is laborious and is only available in expertized facilities. Single 
particle tracking offers a fast possibility to estimate a size profile and 
concentration of an EV sample (Dragovic et al., 2011). Though, this technique 
does not cover the complete size spectrum of EVs and is highly susceptible to 
be biased by co-isolates (Jamaly et al., 2018; van der Pol et al., 2014). Further 
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information about the nature of the vesicles is provided by the presence of the 
tetraspanins CD9, CD63, and CD81, or other genuine EV markers such as 
TSG101, Syntenin or Alix (Jeppesen et al., 2019; Kowal et al., 2016; Tkach et 
al., 2017). Cell type specific markers which are embedded in the membranes 
of the vesicles enable examination of the cell types of origin. Therefore, next 
to straight-forward WB or highly sensitive mass spectrometry proteome 
analysis, microarray or flow cytometry techniques are frequently applied 
(Arraud et al., 2016; Jorgensen et al., 2013; van der Pol et al., 2014). For the 
latter, especially the resolution of conventional flow cytometric devices 
constitutes a main obstacle since particles smaller than 500 nm are hard to 
detect (Erdbrugger et al., 2016; Erdbrugger et al., 2014). Research on this 
topic is evolving fast and new approaches including bead-based assays 
(Koliha et al., 2016) or imaging flow cytometry (IF) (Görgens et al., 2019; 
Lannigan et al., 2017) are developing. Finally, the analysis of proteomic and 
nucleic acid content in plasma EVs by mass-spectrometric profiling or RNA-
seq, respectively, may reveal functional properties. Here similarly, choice of 
isolation technique may confound analysis results (Simonsen, 2017; Van Deun 
et al., 2014). 
In conclusion, plasma-EV isolation and characterization is highly challenging. 
One must carefully consider the combination of EV purification with 
subsequent characterization method in order to prevent contaminants to falsify 
the experimental outcomes. When precautions are taken, blood plasma 
samples offer the possibility to study EV signaling in a variety of physiologic or 
pathophysiologic settings. 
1.4 Extracellular vesicles in physical exercise 
The physiologic changes found during physical exercise are accompanied by 
the liberation of EVs into the circulation. Several studies monitored the release 
of EVs in response to different exercise interventions. Research in humans is 
focused on large platelet and endothelial EVs, also called platelet 
microparticles (PMPs) and endothelial microparticles (EMPs). PMPs are 
demonstrated to increase during physical activity, starting at an early phase of 
exercise and reaching baseline few hours after the exercise session (Wilhelm 
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et al., 2018). Their release can be attributed to the activation of coagulative 
processes (Ahmadizad et al., 2010) and shear stress (Wilhelm et al., 2016) 
during exercise. In contrast, EMPs are mainly found in elevated concentrations 
24 h or longer after an exercise intervention. They are considered to result 
from apoptotic processes and exhibit harmful effects in functional analyses 
(Wilhelm et al., 2018).  
Recently, small EVs have caught attention in the context of physical activity 
and a possible contribution to beneficial adaptations (Piccirillo, 2019; Safdar et 
al., 2018). An increasing number of divergent studies appeared, which 
addressed the release and their possible involvement in signaling pathways. 
In healthy persons, it was shown that physical exercise leads to an acute 
increase of EVs including CD41b-positive platelet-EVs in the human circulation 
while MV numbers remained unchanged immediately after physical activity 
(Frühbeis et al., 2015). In diabetic patients, EVs released in response to 
exercise might carry miRNAs that interfere with MMP9-signaling which leads 
to attenuated fibrosis and myocyte uncoupling (Chaturvedi et al., 2015). 
Furthermore, a 3-weeks swimming protocol compared to a sedentary lifestyle 
of mice enhanced the positive effect of isolated EVs against acute 
ischemia/reperfusion injury in recipient mice (Bei et al., 2017). A set of EV-
associated miRNAs was differentially expressed in the blood of rats after acute 
aerobic exercise and could be involved in the MAPK (mitogen-activated protein 
kinase)-pathway (Oliveira et al., 2018). Addressing muscle-derived EVs, it was 
shown that 1-5 % of EVs released during exercise are α-sarcoglycan (SGCA) 
positive and contain muscle specific miRNAs and/or proteins which could 
indicate involvement in muscle regeneration processes following exercise 
(Guescini et al., 2015). Proteomic analysis of EVs isolated via low-speed 
centrifugation implied that EVs released into the blood after cycling exercise 
comprise muscle-derived EVs transporting myokines to the liver (Whitham et 
al., 2018). However, examination of miRNA changes in circulating small EVs 
after muscle damaging exercise did not reveal alterations in muscle specific 
miRNA species (Lovett et al., 2018). Summarized, these studies provide 
evidence that small EVs are actively released into the blood stream during 
physical exercise, might function as mediators of different key signaling 
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pathways and possibly be involved in adaptation processes triggered by 
exercise. 
1.5 Aim of the study 
Acute physiological chanegs during physical exercise seem to trigger the 
active release of EVs into the circulation which might be involved in 
homeostatic and adaptational tissue-cross-talk. However, detailed knowledge 
on small EV release kinetics, originating cell populations as well as their cargo 
during acute exercise is scarce and putative functions of the liberated EVs in 
target cells remain elusive. Here, a detailed phenotyping of extracellular 
vesicles released upon exhaustive exercise, designated as ExerVs, will be 
performed.  
First, eligible EV purification from human blood plasma to study ExerVs will be 
established. To this end, isolation i) based on size by SEC and ii) based on 
EV-marker presence (CD9, CD63, or CD81) by IA capture will be implemented. 
To further improve purity of EVs, SEC will be combined with iodixanol density 
gradient purification (IDG). Secondly, a modified IA capture isolation protocol 
will be tested. Subsequently, a basic characterization of the differentially 
isolated EVs will be performed via estimation of protein content, WB, NTA or 
EM, where applicable. 
In a second step, release kinetics and origin of ExerVs will be studied in a 
defined cycling exercise setting until exhaustion involving 21 subjects. 
Therefore, WB, NTA, and IF analyses will be implemented and evaluated 
concerning validity. For a detailed phenotyping analysis two multiplexed 
assays, the microarray-based EV Array and the commercial bead-based flow 
cytometric assay MACSPlex, will be applied.  
Based on these examinations, originating cell populations of ExerVs will be 
defined and putative functions of ExerVs as well as their possible involvement 
in beneficial signaling in health and diseases can be postulated. 
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2 Materials and Methods 
2.1 Equipment 
2.1.1 Chemicals 
Table 2.1: Chemicals 
Name Item Source 
1,4-Dithiothreitol (DTT) #6908.2 Carl Roth 
10 % ammonium peroxodisulfate (APS) #9592.2 Carl Roth 
10 x phosphate buffered saline (PBS) #P5493-1L Sigma Aldrich 
20 x NuPAGE MES SDS running buffer #NP0002  Life Technologies 
30 % hydrogen peroxide #8070.2 Carl Roth 
Acrylamide mix 30% (Rotiphorese Gel 30) #3029.1 Carl Roth 
Color prestained protein standard, broad 
range (11–245 kDa) 
#P7712L NEB 
DMEM, high glucose, no glutamine #11960044 Life Technologies 
Ethanol #9065.4 Carl Roth 
Fetal bovine serum (FBS) #10270106 Life Technologies 
H2O ultrapure #W4502 Sigma Aldrich 
L-glutamine 200 mM 100 ml #25030024 Life Technologies 
Milk powder #T145.2 Carl Roth 
N,N,N',N'-tetramethylethylenediamin 
(TEMED) 
#2367.1 Carl Roth 
NuPAGE Novex 4-12% Bis-Tris protein 
gels  #NP0335BOX  Life Technologies 
OptiPrep density gradient solution 60%  #D1556  Sigma Aldrich/ 
Axis-Shield PoC AS 
Penicillin/streptomycin #P0781-100ML Sigma Aldrich 
Ponceau S #P7170 Sigma Aldrich 
RPMI medium 1640 #21875034 Life Technologies 
Sepharose CL-2B #17014001 GE Healthcare 
Silica microspheres, 0.1 µm #24041 Polysciences 
Tween 20 #9127.2 Carl Roth 
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2.1.2 Buffers, media and solutions 
Table 2.2: Buffers, media and solutions 
Buffer/medium/solution Composition 
Homemade enhanced 
chemiluminescence 
(ECL) solution  
Solution A: 50 mg luminol in 200 ml 0.1 M Tris-HCl 
pH = 8.6 
Solution B: 11 mg para-hydroxy coumaric acid in 10 ml 
DMSO (dark) 
ECL solution: combine 1 ml solution A + 100 μl 
solution B + 0.3 μl H2O2 
IDG homogenization 
solution 
250 mM sucrose, 1 mM EDTA, 10 mM Tris-HCl 
IDG working buffer 250 mM sucrose, 6 mM EDTA, 60 mM Tris-HCl 
Lysis buffer LC-MS 20 mM Tris pH 8.0, 1 % SDS, sterile filtered 
Lysis buffer P 50 mM Tris-HCl, pH 8, 120 mM NaCl, 5mM EDTA, 
0.5 % NP-40, sterile filtered 
4 % milk 4 % milk powder in PBS-T 
PBS 150 mM NaCl, 8 mM Na2HPO4, 1.7 mM NaH2PO4, 
pH = 7.2 
PBS-T 0.1 % Tween in PBS 
8 %-polyacrylamide 
separation gel 
For 10 ml (1 gel): 4.6 ml ddH2O, 2.7 ml acrylamide mix 
30 %, 2.5 ml Tris (1.5 M, pH 8.8), 0.1 ml 10 % SDS, 
0.1 ml 10 % APS, 6 μl TEMED 
10 %-polyacrylamide  
separation gel 
For 10 ml (1 gel): 4 ml ddH2O, 3.3 ml acrylamide mix 
30 %, 2.5 ml Tris (1.5 M, pH 8.8), 0.1 ml 10 % SDS, 
0.1 ml 10 % APS, 4 μl TEMED 
12 %-polyacrylamide 
separation gel 
For 10 ml (1 gel): 3.3 ml ddH2O, 4 ml acrylamide mix 
30 %, 2.5 ml Tris (1.5 M, pH 8.8), 0.1 ml 10 % SDS, 
0.1 ml 10 % APS, 4 μl TEMED 
5 %-polyacrylamide 
stacking gel 
For 3 ml (1 gel): 2.1 ml ddH2O, 0.5 ml acrylamide mix 
30 %, 0.38 ml 1.0 M Tris pH 6.8, 0.03 ml 10 % SDS, 
0.03 ml 10 % APS, 3 μl TEMED 
5 x SDS running buffer for 
electrophoresis 
125 mM Tris, 1.25 M glycine, 0.5 % SDS, pH = 8.3 
WB transfer buffer 24 mM Tris, 192 mM glycine, 20 % ethanol in dH2O 
4 x WB sample buffer  200 mM Tris-HCl, pH = 6.8, 10 % SDS, 0.4 % 
bromophenol blue, 40 % glycerol, if reducing 
conditions desired: 400 mM DTT 
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2.1.3 Materials 
Table 2.3: Materials 
Material Item Manufacturer 
µ columns with plungers #130-042-701 Miltenyi Biotec 
0.22 µm PES-filter membranes #CX07.1 Merck Millipore 
Amicon Ultra-4, regenerated cellulose 
membrane, 10 kDa pore size 
#UFC801024 Merck Millipore 
Amicon Ultra-15, regenerated cellulose 
membrane, 100 kDa pore size 
#UFC910024 Merck Millipore 
BCA Protein Assay Kit #71285-3 Merck 
Millipore/Novagen 
Clear-view Snap-Cap micro tubes, 1.5 ml, 
low retention 
#T4816-250EA Sigma Aldrich 
Exosome Isolation Kit, human (CD63) #130-110-918 Miltenyi Biotec 
Exosome Isolation Kit, human (CD81) #130-110-914 Miltenyi Biotec 
Exosome Isolation Kit, human (CD9) #130-110-913 Miltenyi Biotec 
MACSPlex Exosome, Kit, human #160-001-032 Miltenyi Biotec 
Monovettes: 
S-Monovette 7.5 ml K3E 
S-Monovette 2.7 ml K3E 
S-Monovette 7.5 ml Z-Gel 
Microvette CB 300 K2E 
 
#01.1605.001 
#05.1167 
#01.1602 
#16.444 
Sarstedt 
Plastic capillary 20 μl, sodium-heparinized #7111-0011-20H EKF Diagnostics 
Polyallomer UC tubes, 14 ml #331374 Beranek/Beckman 
Coulter 
Protein LoBind Tubes 5.0 ml, PCR clean #525-0792 Eppendorf 
PVDF-membrane Immobilon-P, 0.45 μm 
pore size 
#IPVH00010  
 
Merck Millipore 
Safety-lancet, normal, 21 G, 1.6 mm #85.1016 Sarstedt 
Safety-Multifly needle, 21 G 200 mm #85.1638.235 Sarstedt 
Syringe 10 ml #613-3931  VWR 
X-ray films Hyperfilm ECL #28-9068-37 VWR/Amersham 
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2.1.4 Antibodies 
Table 2.4: Primary antibodies used in western blotting 
Antigen Clone Host species Dilution Manufacturer 
Alix 49/AIP1 mouse 1:1000 BD 
ApoA1 12C8 mouse 1:200 Santa Cruz 
ASGPR2 C-4 mouse 1:200 Santa Cruz 
CD9 MM2/57 mouse 1:2000 Merck Millipore 
CD41b SZ.22 mouse 1:1000 Santa Cruz 
CD63 RFAC4 mouse 1:500 Merck Millipore 
CD81 B-11 mouse 1:1000 Santa Cruz 
Calnexin polyclonal rabbit 1:1000 Enzo 
Flotillin-1 polyclonal rabbit 1:1000 Sigma 
HSP70 7/Hsp70 mouse 1:1000 BD 
Na/K-ATPase 464.6 mouse 1:5000 Novus Biologicals 
SGCA D-7 mouse 1:500 Santa Cruz 
Syntenin polyclonal rabbit 1:2000 Abcam 
TSG101 4A10 mouse 1:1000 GeneTex 
 
Table 2.5: Secondary antibodies used in western blotting 
Host 
species 
Target 
species Conjugation Dilution Cat. No. Manufacturer 
goat mouse HRP 1:10,000 115-035-166 Dianova 
mouse rabbit HRP 1:10,000 211-032-171 Dianova 
 
Table 2.6: Primary antibodies included in EV Array analysis 
Antigen Clone Manufacturer Info 
Alix #3A9 Biolegend EV marker 
Annexin V  polyclonal R&D Systems Antibody against Annexin V, 
not phosphatidylserin 
Apo E  #395004 R&D Systems Lipoprotein marker 
CAIX #2D3 Abcam Carbonic anhydrase 
Cathepsin D  polyclonal R&D Systems Lysosome 
CAXII #315602 R&D Systems Carbonic anhydrase 
CD14 #M5E2 BD Biosciences TLR4 co-receptor, 
monocytes 
CD142 #323514 R&D Systems Tissue factor, endothelial 
cells, leukocytes 
CD146 #P1H1 Abcam Cell surface glycoprotein 18, 
endothelial cells 
CD151 #210127 R&D Systems Tetraspanin 
CD171 polyclonal Sigma-Aldrich L1 protein, cell adhesion 
CD235a #R10 R&D Systems Glycophorin A, erythrocytes 
CD31 polyclonal R&D Systems PE-CAM1, platelets, 
endothelial cells 
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CD4 #34930 R&D Systems T cells(, monocytes) 
CD42a polyclonal LS Bio, Seattle Glycoprotein 9, von 
Willebrand factor (vWF)-
receptor, platelets 
CD42b #486805 R&D Systems Glycoprotein 1b, von vWF, 
platelets 
CD45 #2D1 R&D Systems Proteintyrosine 
phosphatase C, leukocyte 
common antigen, B cells, 
T cells 
CD62E/P #BBIG-E6 R&D Systems E and P-selectin, 
endothelial cells, platelets 
(activated) 
CD62E #1.2B6 Thermo Scientific E-selectin, endothelial cells 
CD63 #MEM-259 Bio-RAD Tetraspanin, EV marker 
CD81 #1.3.3.22 Ancell Tetraspanin, EV marker 
CD82 #423524 R&D Systems Tetraspanin, EV marker 
CD8a #37006 R&D Systems T cell receptor co-receptor, 
cytotoxic T cells, NK cells, 
DCs 
CD9 #SN4/C3-3A2 Ancell, Bayport Tetraspanin, EV marker 
EpCAM #0.N.277 Santa Cruz CD326, Epithelial cell 
adhesion molecule 
Flotillin-1 polyclonal Abcam EV marker 
GRP78 #N-20 Santa Cruz Binding immunoglobulin 
protein, chaperone, ER 
HLA-ABC #W6/32 Biolegend MHCIa 
HLA-DR #L243 Biolegend MHCII 
HLA-DRDPDQ #HB-145 Loke Diagnostics MHCII 
Hsp70 polyclonal Assay Design Chaperone, EV marker 
Hsp90 polyclonal Abcam Chaperone, EV marker 
ICAM-1 #R6.5 eBioscience CD54, endothelial cells and 
immune cells 
LAMP-1 #508921 R&D Systems Lysosomal membrane 
protein, late endosome and 
MVB marker 
LFA1 #HI111 Ab Biotec Lymphocyte function-
associated antigen 1 
TGFb1 #A75-2 BD Pharmingen Transforming growth 
factor β, cytokine 
TLR3 #TLR3.7 Santa Cruz Anti-viral response, binds 
dsRNA 
tPA polyclonal R&D Systems Tissue plasminogen 
activator, conversion of 
plasminogen to plasmin, 
anti-coagulation, endothelial 
cells 
TSG101 polyclonal Abcam EV marker 
VE-Cadherin polyclonal R&D Systems CD144, endothelial cells 
VEGFR2 #7D4-6 Biolegend Endothelial cells, 
angiogenesis 
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Table 2.7: Capture antibodies included in the MACSPlex analysis (MACSPlex 
exosome human kit, Milteny Biotec) 
Antigen Antibody 
isotype 
Info 
CD1c mIgG2a Glycoprotein, APC 
CD2 mIgG2b Cell adhesion molecule, T cells, NK cells 
CD3 mIgG2a T cell co-receptor 
CD4 mIgG2a Glycoprotein, T cells(, monocytes) 
CD8 mIgG2a Transmembrane glycoprotein, T cell receptor co-
receptor, cytotoxic T cells 
CD9 mIgG1 Tetraspanin, EV marker 
CD11c mIgG2b Integrin αX, DCs, leukocytes 
CD14 mIgG2a TLR4 co-receptor, monocytes 
CD19 mIgG1 B-lymphocyte antigen 
CD20 mIgG1 B-lymphocyte antigen 
CD24 mIgG1 Signal transducer 24, sialoglycoprotein, B cells 
CD25 mIgG1 Interleukin-2 receptor α chain, lymphocytes 
CD29 mIgG1K integrin β-1, cell surface receptor 
CD31 mIgG1 PE-CAM1, platelets, endothelial cells 
CD40 mIgG1K Protein receptor, AP cells 
CD41b REA integrin αIIβ, platelets 
CD42a REA Glycoprotein 9, vWF-receptor, platelets 
CD44 mIgG1 AP cells, immune signaling 
CD45 mIgG2a Proteintyrosine phosphatase C, leukocyte 
common antigen, B cells, T cells 
CD49e mIgG2b integrin α-5 
CD56 REA ICAM-1, endothelial cells and immune cells 
CD62P REA P-selectin, platelets (activated) 
CD63 mIgG1K Tetraspanin, EV marker 
CD69 mIgG1K transmembrane C-type lectin protein, immune 
cells 
CD81 REA Tetraspanin, EV marker 
CD86 mIgG1 AP cells, T cell activation 
CD105 mIgG1 Endoglin, type I membrane glycoprotein, 
endothelial cells 
CD133/1 mIgG1K Prominin-1, glycoprotein 
CD142 mIgG1K Tissue factor, endothelial cells, leukocytes 
CD146 mIgG1 Cell surface glycoprotein 18, endothelial cells 
CD209 mIgG1 Dendritic Cell-Specific Intercellular adhesion 
molecule-3-Grabbing Non-integrin, C-type lectin 
CD326 mIgG1 Epithelial cell adhesion molecule 
HLA-ABC REA MHCI 
HLA-DRDPDQ REA MHCII 
MCSP mIgG1 melanoma-associated chondroitin sulfate 
proteoglycan 
ROR1 mIgG1K Tyrosine-protein kinase transmembrane receptor 
SSEA-4 REA Stem cells 
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2.1.5 Devices 
Table 2.8: Devices 
Type Name Manufacturer 
Centrifuge Centrifuge 5810R; rotor FA-45-24-11 Eppendorf 
Centrifuge Centrifuge 5424R; rotors FA-45-6-30, 
A-4-81, A-2-DWP 
Eppendorf 
Centrifuge Hettich Universal 320 R Andreas Hettich  
Centrifuge  Tabletop Biofuge fresco Heraeus 
Centrifuge  Centrifuge ZK496 Hermle 
Cycling ergometre Ergoselect 200  Ergoline 
Electronic pipette  Single channel electronic pipette E4 XLS Rainin 
Flow cytometer MACSQuant Analyzer 10  Miltenyi Biotec 
Lactate biosensor Biosen 5140  EKF Diagnostics 
Magnetic stand µMACS Separator Miltenyi Biotec 
Nanoparticle 
tracking 
Nanosight LM10 system, camera model 
Hamamatsu C11440-50B/A11893-02, 
532 nm laser 
Malvern 
pH meter pH meter Lab 850 Schott 
Plate reader Tecan Infinite M200 Pro Life Science 
Refractometre Refractometer T; Refractometer 2T Atago 
SDS-PAGE system Mini-PROTEAN TetraVertical 
electrophoresis cell 
Bio-Rad 
SDS-PAGE system XCell SureLock Mini-Cell electrophoresis 
system 
Invitrogen 
Thermocycler  CFX384 Touch real-time PCR detection 
system 
Bio-Rad 
Ultracentrifuge Optima L-90 K ultracentrifuge; SW40 Ti 
rotor  
Beckman Coulter 
WB system Mini Trans-Blot cell Bio-Rad 
X-ray film processor Optimax Typ TR x-ray film processor MS Laborgeräte 
2.1.6 Software 
Table 2.9: Software 
Software Developer 
Blue Cherry  Geratherm Respiratory 
CorelDRAW X7 Corel Corporation 
FiJi ImageJ 64 V5 Open source, NIH 
GraphPad PRISM Graphpad Software 
JMP SAS 
MACSQuantify software  Miltenyi Biotec 
Nanosight 2.3 software Malvern 
R Studio Version 3.5.0 RStudio Inc 
Winlactat  Mesics GmbH, Münster 
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2.2 Study design 
2.2.1 Study participants 
Study participants were recruited by employees of the department of sports 
medicine, Mainz, in training hours of the university sports as well as during 
regular performance diagnostics. Healthy male persons aged between 20 and 
40 years with regular exercise training were included. Participants should be 
non-smokers and absent from medication for at least two weeks. They were 
informed orally and in writing about the procedure as well as possible 
complications and signed a consent form for participating in the study. 
2.2.2 Study procedure 
Several criteria were implemented in favor of standardization of the study 
procedure. To exclude an influence of the circadian rhythm on study outcomes, 
all tests were performed between 8 and 10 am. An acute impact of the diet on 
results was avoided by at least eight hours of over-night fasting. Participants 
should not be exposed to exhaustion prior to the test to ensure proper 
estimation of resting values. To this end they abstained from exercise training 
for 24 h, chose a non-exhaustive way to arrive at the department of sports 
medicine and rested for a minimum of 30 min before the first blood drawl. Prior 
to the exercise tests a medical examination including anamnesis, estimation 
of lung function, electrocardiography and blood pressure at rest as well as 
bioelectrical impedance analysis was performed.  
2.2.3 Exhaustive exercise setting 
The athletes were subjected to an incremental cycling test until exhaustion 
which was indicated subjectively by the participant. The tests were conducted 
on a cycling ergometer ergoselect 200. The standard exercise protocol 
comprised a starting power of 40 W and increasing levels by 40 W every 3 
minutes. In few cases during pilot experiments the exercise protocol was 
adapted to the athletes’ physical fitness. Borg values were stated by the 
subject at the end of each 3 min-level. Heart rate, blood pressure and 
electrocardiography were recorded, which gave the supervisor the possibility 
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to abort exertion in case of anomalies that could expose the participant to 
health risk. Also, respiratory analysis was implemented to monitor ventilatory 
equivalents. Estimation of respiratory data was done using the Blue Cherry 
software.  
2.2.4 Blood sampling 
Venous blood collection was performed at three time points. Prior to the test, 
blood was drawn at resting conditions during the medical examination. During 
the test, when a respiratory quotient of 0.9 was reached, the second venous 
blood drawl was performed. The third venous blood drawl was performed 
within 2 min after exhaustion and completion of the test. In indicated 
experiments, additional venous blood was taken at a recovery time after 
exhaustion. In this case, participants were kept at resting conditions after the 
test. For venous blood collection 33 ml of blood were obtained from the median 
cubital vein with a Safety-Multifly needle (0.8 × 19 mm) and collected in 
tripotassium-EDTA covered Monovettes and serum-gel Monovettes. 
Capillary blood sampling was performed for lactate and/or cfDNA estimation. 
For assessment of lactate levels 20 μl of capillary blood were collected from 
the earlobe in sodium-heparinized capillaries and for cfDNA measurement 
30 µl of capillary blood were collected with a dipotassium-EDTA covered 
Microvette CB 300 from the fingertip. Time points were prior to the test (for 
lactate and cfDNA), at the end of each 3 min level (for lactate and cfDNA), 
immediately after exhaustion (for lactate and cfDNA), and 3 min (for cfDNA 
only), 10 min (for cfDNA only) as well as 20 min (for cfDNA only) after 
exhaustion.  
2.2.5 Blood cell counts, physiologic and metabolic parameters 
Venous blood in serum-tubes and EDTA-tubes were sent to routine 
diagnostics in order to receive metabolic parameters and blood cell counts of 
the participants at rest and exercising conditions. 
Blood lactate levels were assessed with the lactate analyser Biosen 5130 and 
evaluated with winlactate software. The individual anaerobic threshold was 
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determined at a net increase of lactate concentration of 1.0 mmol/l above 
lactate concentration at lactate threshold (Roecker et al., 2003). 
2.2.6 Cell-free DNA 
For cell-free DNA (cfDNA) analysis capillary blood was centrifuged 2 min at 
1,600 x g at 4 °C and plasma was stored at -80 °C until measurement. Nucleic 
acid concentration was measured by Dr. Elmo Neuberger (Sports Medicine, 
Mainz, Germany) applying direct quantitative polymerase chain reaction 
(qPCR) of the L1PA2-repeat as published in Breitbach et al. with few changes. 
2 µl of diluted plasma (1:10 in H2O) were mixed with 13 µl of qPCR-mastermix 
(final concentrations: Velocity polymerase 0.6 u, 1.2x Hifi buffer, 0.15x SYBR 
Green, 0.001x FITC, 0.3 mM dNTPs, 0.15 µM primer-mix) and analyzed in 
triplicates in a final volume of 5 µl. Amplification of the 90 bp L1PA2 fragment 
was performed using the CFX384 thermocycler with 2 min 98 °C, followed by 
10 s 95 °C and 10 sec 64 °C for 35 cycles (Breitbach, Tug, et al., 2014). 
2.2.7 Preparation of platelet free plasma 
To prevent platelet degranulation, venous blood in EDTA-tubes was kept 
vertically on room temperature (RT) avoiding agitation. To obtain platelet free 
plasma two consecutive centrifugation steps of 15 min at 2,500 x g at RT were 
performed. First centrifugation was started within 15 min after blood collection. 
Plasma was collected leaving 1 ml of plasma in the tube to avoid contamination 
with cells from the buffy coat. Then the collected plasma was subjected to a 
second centrifugation. The supernatant was collected and again, 0.5 ml were 
left in the tube to avoid carry-over of remaining blood cells. The prepared 
platelet-free plasma was kept on ice until EV preparation or frozen at -80°C.  
2.3 Cell culture and primary cell isolation 
2.3.1 K562 cells 
The cell line K562 originates from a 53-year-old female patient suffering from 
acute myelogenous leukaemia (Lozzio et al., 1979). K562 cells display 
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erythroleukaemia type and cultivation enables differentiation to cells with 
monocyte, granulocyte, and erythrocyte characteristics (Lozzio et al., 1981). 
Cultivation of K562 cells was performed in DMEM medium supplemented with 
10 % fetal bovine serum (FBS), 1 % L-glutamine and 1% 
penicillin/streptomycin in concentrations from 2-10 x 105/ml. Cells were grown 
at 37 °C and 5 % CO2. For passaging of cells, cell-containing medium was 
centrifuged for 5 min at 300 x g at RT. The supernatant was discarded and the 
cell pellet was diluted in fresh medium to the desired cellular concentration. 
For the preparation of conditioned cell culture supernatant (CCS), cells were 
washed twice in PBS (resuspended and centrifuged for 5 min 300 x g RT) and 
subsequently seeded in a concentration of 5 x 105 cells/ml in medium 
supplemented with L-glutamine only. After 24 h conditioned CCS was collected 
by centrifugation for 5 min at 300 x g at RT and pre-cleared either by 
centrifugation for 15 min at 2,500 x g (protocol P1) or 30 min at 10,000 x g with 
filtering at 0.22 µm (P2). The cell pellets were washed in ice cold PBS, 
centrifuged at 300 x g for 5 min and used for cell lysate preparation (see 
chapter 2.3.4). 
2.3.2 THP1 cells 
The THP1 cell line is derived from immortalized cells isolated from the 
peripheral blood of a one year old boy suffering from acute monocytic 
leukaemia (Tsuchiya et al., 1980). THP1 cells exhibit characteristics of 
monocytic progenitor cells and can be differentiated to adherent macrophage-
like cells induced by the stimulation with phorbol 12-myristate 13-acetate 
(Tsuchiya et al., 1982; Tsuchiya et al., 1980). 
THP1 cells were cultured in RPMI1640 medium supplemented with 10 % FBS, 
1 % L-glutamine and 1 % pen/strep in concentrations from 1-10 x 105cells/ml. 
Cells were incubated at 37 °C and 5 % CO2. For passage of cells, cell-
containing medium was subjected to a centrifugation of 5 min at 300 x g at RT. 
The supernatant was discarded, and the cell pellet was diluted in fresh medium 
to the desired cellular concentration.  
To obtain cell lysates, cell pellets were washed in ice cold PBS, centrifuged 
again for 5 min at 300 x g and used for subsequent lysate preparation (see 
chapter 2.3.4). 
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2.3.3 Ex vivo platelet preparation 
Platelet-preparation from fresh venous blood was performed by polysucrose 
density gradient centrifugation. The gradient was prepared by layering 3.5 ml 
1.119 g/ml sucrose (Histopaque-1119) with 3 ml 1.077 g/ml sucrose 
(Histopaque-1077) in a 15 ml tube (fig. 2.1). After blood withdrawal (see 
chapter 2.2.4) 6 ml were carefully layered on top of the gradient and 
centrifuged for 30 min at 700 x g and 19 °C without brake. Then, the upper 
phase (= blood plasma) was discarded and the second phase, which contained 
mononuclear cells and platelets, was transferred into a fresh 15 ml tube. After 
a washing step in PBS by centrifugation at 300 x g for 10 min, the platelet-
containing supernatant was transferred into a fresh 15 ml tube. Finally, 
platelets were pelleted at 3,000 x g for 5 min. 
 
Figure 2.1: Principle of cell separation by density gradient centrifugation. Blood 
is layered on top of a gradient consisting of 1.119 g/ml sucrose (Histopaque-1119) 
and 1.077 g/ml sucrose (Histopaque-1077). After centrifugation, cellular phases are 
separated by the sucrose solutions due to their density. 
2.3.4 Cell lysate preparation 
For cell lysate preparation, cell pellets from cell culture or ex vivo platelet 
preparation were resuspended in 100 µl lysis buffer P (see tbl. 2.2) and 
incubated for 15 min on ice. After centrifugation for 15 min at 13,000 x g and 
4 °C, the supernatant was stored at -20 °C for further analysis, the pellet was 
discarded. 
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2.4 Methods for EV isolation 
The preparation of EVs from human blood plasma or cell culture supernatant 
was performed by applying different methods of EV enrichment, which are 
described in the following.  
To reduce loss of whole vesicles or vesicle associated markers and cargo 
during the isolation process, several points were considered. In general, EV-
containing sample material or isolated EVs were placed on ice or 4 °C to inhibit 
enzymatic processes. Furthermore, elution volume was kept at a minimum, 
and low-binding tubes were used to prevent EVs from sticking to the plastic 
surface of the tubes. In addition, excessive vortexing of samples was avoided 
and centrifugal speed was kept at a minimum whenever possible to hold EVs 
as intact as possible. Finally, isolated EVs which were not applied to 
downstream analysis were immediately stored at -80 °C. 
2.4.1 Ultrafiltration 
EV enrichment by ultrafiltration (UF) was performed in 10 kDa (0.5 ml and 4 
ml loading capacity) or 100 kDa (15 ml loading capacity) Amicon filter devices. 
Depending on the starting volume of a sample and the volume of the final 
concentrate, Amicon filter devices with loading capacities of 0.5 ml, 4 ml, 15 ml 
or a gradual use of the named were applied. Prior to the use, filters were 
washed with PBS. Then, CCS or pooled SEC fractions (see chapter 2.4.2) 
were loaded onto the filter and centrifugation was performed at 5,000 x g until 
the desired volume was reached. After discarding the flow-through, filters were 
re-loaded with sample material to further elevate concentration. In addition, 
PBS was added to wash the concentrate in two washing steps. Depending on 
the used filter device, EV concentrate was eluted by reverse-spin of the 
Amicon for 2 min at 5,000 x g (0.5 ml-Amicon) or pipetting of the eluate directly 
from the filter cone (4 ml- and 15 ml-Amicon). In case of EV enrichment from 
plasma, filters were discarded after use. In case of EV enrichment from CCS, 
filters were incubated in 0.1 % SDS overnight, washed twice and stored in 
particle free dH2O until re-use. 
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2.4.2 Size exclusion chromatography 
EV isolation by SEC was implemented using self-made SEC columns based 
on the protocol published by Boing et al. (2014) with modifications (illustrated 
in fig. 2.2) (Boing et al., 2014).  
SEC columns were packed in a 10 ml-syringe tube placing a 0.22 µm 
polyethersulfone (PES)-filter membrane at the bottom of the syringe. For one 
column 15 ml of Sepharose CL-2B suspension (in 20 % ethanol) was mixed 
with 5 ml of particle free PBS and gradually filled into the tube to receive a 
column volume of 10 ml of sepharose. Sepharose was then washed by 
applying 10 ml of PBS onto the surface while discarding the flow-through. 
Prepared SEC columns were either used immediately or stored overnight at 
4 °C in an appropriate volume of PBS and covered with parafilm to prevent 
draining. 
A sample volume of 2 ml was applied to the column, which was either platelet 
free plasma, UF-EVs from CCS (pre-enriched in 15 ml-Amicons, 100 kDA, see 
chapter 2.4.1) or fractions recovered from a density gradient (see chapter 
2.4.3). 1 ml-fractions were collected to define EV-rich fractions by analysis of 
particle count using nanoparticle tracking analysis, protein content applying 
BCA assay, and presence of vesicular and non-vesicular markers by western 
blotting. Depending on the volume needed for each downstream analysis 
method, SEC fractions were further concentrated applying ultrafiltration (0.5 or 
4 ml-Amicons, 10 kDa, see chapter 2.4.1). 
Analyzing plasma EVs, fractions 4 to 6 were considered EV-rich while plasma-
protein and lipoprotein poor, as specified in the results section. To reduce the 
complexity of the methodical set-up, in subsequent sample preparation the first 
3 ml (#1-3) of SEC flow-through were discarded and the second 3 ml (#4-6) 
were collected as “SEC-EVs”. Subsequently, pooled fractions 4 to 6 were 30-
fold concentrated to receive a final volume of 100 µl of SEC-EVs.  
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Figure 2.2: Principle of EV isolation by size exclusion chromatography. EVs are 
separated due to their size and interaction characteristics with the column matrix 
consisting of agarose spheres. Big particles elute first, small vesicles follow, smaller 
lipoproteins and plasma proteins elute in the later fractions. 2 ml of EV-containing 
sample are loaded on a column and 1 ml-fractions are collected for further 
analysis. The pool of fractions 4 to 6 is defined as SEC-EVs. 
2.4.3 Iodixanol density gradient centrifugation 
EVs were enriched using SEC in combination with discontinuous iodixanol 
gradient centrifugation (adapted from Vergauwen et al., unpublished data; 
IDG-step illustrated in fig. 2.3). The gradient was prepared by carefully layering 
different solutions of iodixanol (3 ml of 40 %, 3 ml of 20 %, 3 ml of 10 % and 
2.5 ml of 5 % OptiPrep) in 14 ml-UC tubes. These were prepared by dilution of 
the 60 % OptiPrep stock solution with IDG working solution buffer and 
homogenization medium as specified by the manufacturer (Axis-Shield PoC 
AS, also see tbl. 2.2). Subsequently, 0.5 ml of the concentrated SEC eluate 
was loaded on top of the gradient. The samples were then centrifuged for 18 h 
at ~100,000 x g and 4 °C (Optima L-90K Ultracentrifuge, rotor SW40 Ti, 
average of 106,154 x g, maximum of 149,576 x g, k-factor 260). After 
centrifugation 1 ml-fractions were collected from the top of the gradient and 
density was determined using a refractometer. Iodixanol was removed from 
the fractions by SEC. As described in Vergauwen et al. (2017), SEC fractions 
4-7 are considered iodixanol-free and were used for vesicle enumeration using 
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NTA. Enrichment of EVs after removal of iodixanol was performed using 
ultracentrifugation (Vergauwen et al., 2017).  
 
 
Figure 2.3: Principle of iodixanol gradient centrifugation. Different 
concentrations (%) of iodixanol are layered with the pre-enriched EV sample. After 
centrifugation 1 ml-IDG fractions containing EV-poor phase and EV-rich phase can 
be collected and further analyzed. 
2.4.4 Ultracentrifugation 
Pre-processed plasma EV samples were enriched by ultracentrifugation 
implementing a spin at ~100,000 x g (Optima L-90K Ultracentrifuge, rotor 
SW40 Ti, average of 106,154 x g, maximum of 149,576 x g, k-factor 260) and 
4 °C for 2 h. Prior to centrifugation, samples were diluted to 13 ml in PBS in 
UC tubes. For further analysis, pelleted EVs were resuspended in PBS or WB 
sample buffer by pipetting 50 times up and down using an automatic pipette. 
2.4.5 Immuno-affinity capture 
EV preparation by IA capture was performed using the CD9-, CD63- or the 
CD81-Exosome Isolation Kit (Miltenyi Biotec, principle illustrated in fig. 2.4 a). 
2 ml of undiluted platelet-free plasma were mixed with 50 µl of CD9-, CD63-, 
or CD81-antibody-coupled magnetic beads and incubated for 1 h at RT with 
constant shaking and absent from light. µ-columns were set-up on a magnetic 
stand and washed as specified in the kit instructions. The mix of plasma and 
isolation-beads was added to the µ-column and the flow-through was 
discarded. After washing, the µ-column was removed from the magnetic stand 
and elution was performed applying 100 µl isolation buffer and pushing the 
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plunger into the column (standard elution). Alternatively, EV elution was 
performed directly at the magnetic stand in lysis buffer LC-MS (see tbl. 2.2) in 
order to retain the magnetic beads in the µ-column (modified elution, illustrated 
in fig. 2.4 b). The final elution volume was 130 µl of CD9+EVs, CD63+ EVs or 
CD81+EVs. 
 
Figure 2.4: Principle of EV isolation by immuno-affinity capture. After magnetic 
labeling of EVs with beads conjugated to CD9, CD63 or CD81 antibodies, EVs are 
separated from plasma by magnetic separation. Elution of EVs is performed (a) 
detached from the magnet by applying isolation buffer/PBS or (b) directly at the 
magnet by applying LC-MS buffer. 
 
2.5 Methods for EV characterization 
2.5.1 Electron microscopy 
Electron microscopy imaging was performed by Wiebke Möbius (Max Planck 
Institute of Experimental Medicine, Göttingen, Germany). SEC-EVs were fixed 
with 4 % paraformaldehyde and adhered to 100 mesh copper-grids for 5 min. 
Analysis was performed by transmission electron microscopy after 10 washing 
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steps with H2O and embedding in 2 % methylcellulose with 0.4 % uranyl 
acetate. 
2.5.2 Nanoparticle tracking analysis 
EVs were subjected to NTA using the Nanosight LM10 system (camera model 
Hamamatsu C11440-50B/A11893-02) equipped with a 532 nm laser as well 
as the Nanosight 2.3 software. The temperature was controlled and constantly 
kept at 23 °C. A syringe pump was implemented in combination with the script 
control “Repeatstart, Syringeload 500, Delay 5, Syringestop, Delay 15, 
Capture 30 and Repeat 4”. Particle tracking was performed with camera 
control standard settings at camera level 14. Five videos of 30 s were 
recorded, particles were tracked, and detection was performed at detection 
threshold 8 and minimum expected particle size “auto”. Average values from 
these five measurements were formed for particle concentration as well as 
mode and mean particle size. EV samples were diluted in particle-free PBS to 
obtain a particle concentration of 3-10 x108 particles/ml. Measurements were 
verified utilizing silica microspheres with a size of 100 nm as described in 
Gardiner et al. 2013 (Gardiner et al., 2013). 
2.5.3 Imaging flow cytometry 
The enumeration of EVs using imaging flow cytometry was performed by Rita 
Ferrer Tur and Andre Görgens at the Institute for Transfusion Medicine, 
University Hospital Essen on an Amnis ImagestreamX MkII. To this end EVs 
in plasma and SEC-EVs (each diluted 1:10 in PBS) were fluorescently labelled 
with BODIPY in 10 µM final concentration. After further dilution in PBS total 
EVs and EV subclasses were measured with the Amnis as described in 
Görgens et al., 2019 (Görgens et al., 2019). 
2.5.4 Total protein content 
Protein content of EV preparations was estimated using the Novagen BCA 
Protein Assay Kit according to the manufacturer’s instructions implementing 
the enhanced assay protocol. The Tecan Infinite M200 Pro was used for the 
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measurement (Nunclon 96 flat bottom plates, absorbance at 562 nm, 5 flashes 
per well). 
2.5.5 Western blotting 
Differentially obtained EV-containing samples and cell lysates as antibody 
positive controls (K562-, THP1-cells and ex vivo platelets) were mixed with WB 
sample buffer (tbl. 2.2) and subjected to SDS-PAGE (sodium dodecyl sulfate–
polyacrylamide gel electrophoresis) on self-made 8 %, 10 % and 12 % gels 
(buffer: 1x SDS running buffer for electrophoresis, tbl. 2.2) or pre-cast 4-12 % 
NuPAGE Novex 4-12 % Bis-Tris gels (buffer: NuPAGE MES SDS running 
buffer, tbl. 2.2). Proteins from the gel were transferred on a PVDF-membrane 
using Bio-Rad western blotting system (buffer: Western blotting transfer buffer, 
tbl. 2.2). To verify proper transfer of proteins, ponceau staining was performed 
by incubation with ponceau solution for 5 min followed by two washing steps 
of 1 min in H2O. Membranes were then blocked with 4 % milk for 30 min. 
Incubation of primary antibodies (tbl. 2.4) in 4 % milk in PBS-T was performed 
for 2-3 h at RT or overnight at 4 °C. After three washing steps in PBS-T for 
10 min, secondary antibody (tbl. 2.5) in 4 % milk in PBS-T was incubated for 
30 min at RT. Subsequently, chemiluminescent detection was implemented by 
2 min incubation of the membrane in ECL (tbl. 2.2) and visualization with x-ray 
films on an x-ray film processor. If applicable, the membrane was re-stained 
with a primary antibody for a different marker protein after a washing step in 
4 % milk. For semi-quantitative evaluation, signals were normalized to sample 
volume (plasma-EVs) or NTA particle amount (K562-EVs) and analyzed in 
ImageJ software. Immuno-stainings showing high background noise were 
excluded from semi-quantitative analysis (e.g. presented CD9+EVs Syntenin 
staining, fig. 3.17). 
2.5.6 EV Array 
EV Array experiments were performed by Dr. Malene Jorgensen and Rikke 
Baek (Department of Clinical Immunology, Aalborg University Hospital, 
Denmark) as described in Baek and Jorgensen, 2017 (Baek et al., 2017; 
Jorgensen et al., 2013). Shortly, EV containing plasma samples are applied to 
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epoxy-silane-coated microarray slides and EVs are captured by the coated 
antibodies depending on their specific surface marker proteins. Subsequently, 
a cocktail of biotinlabeled detection antibodies against the exosomal markers 
CD9, CD63, and CD81 is applied. Finally, fluorescently labeled streptavidin is 
added and detection of the captured EVs is performed. 10 µl of platelet free 
plasma were used to analyze the presence of 41 marker proteins (see tbl. 2.6).  
Analysis of EV Array data was modified from the original procedure as follows. 
First, the mean fluorescence intensities of a marker for the included controls 
(first: washing buffer on coated microarray spots; second: plasma on uncoated 
microarray spots) were calculated. The limit of detection (LOD) for a marker in 
a sample was then set to the fluorescence intensity at 3-times the standard 
deviation above the mean of each of the control samples. Further statistical 
analysis (see chapter 2.6) was restricted to those candidates that reached a 
mean fluorescence intensity above this LOD. 
2.5.7 MACSPlex assay 
MACSPlex analysis was performed using the MACSPlex Exosome, human, 
Kit (Miltenyi Biotec) according to the kit specifications (fig. 2.5). 120 µl of SEC-
EVs and 50 µl of immuno-captured beads were used for MACSPlex-analysis. 
Accordingly, comparison between time points of analysis (pre, RQ, post) was 
based on sample volume. PBS was included as a background control sample. 
Samples were incubated overnight with 15 µl of the capture antibody mix (list 
of included capture antibodies in tbl. 2.7) in a total volume of 135 µl at RT with 
constant shaking and absent from light. After removal of excessive capture 
antibodies by a washing step, 15 µl of a mix of CD9-, CD63, and CD81-APC 
detection antibodies was added and incubated likewise in a total volume of 
150 µl. After another washing step, flow cytometric analysis was carried out in 
round-bottom 96-well plates on the MACSQuant Analyzer 10 (Miltenyi Biotec) 
with the corresponding software, implementing the MACSPlex exosome 
application. Bead counts were monitored and values with counts below 10 
were excluded from further analysis. For the evaluation of mean fluorescence 
intensities, background values of the control sample of each run was 
subtracted from the sample values. Surface marker values below the 
corresponding control antibody, considered as measurement threshold, were 
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regarded as negative. For the capture antibodies CD4 and CD14, data series 
in which the RQ 0.9 and/or post exercise values were clearly above the 
threshold, pre-values were included despite being under the threshold. 
 
 
Figure 2.5: Principle of the MACSPlex assay. Isolated EVs are captured by color-
coded beads carrying specific antibodies for cell surface markers (e.g. CD4, CD41b, 
CD45). Subsequently, detection antibodies for the EV markers CD9, CD63 and CD81 
conjugated to the fluorophore APC bind to the EVs. Using flow cytometry, the surface 
marker profile of the sample is visualized. 
2.5.8 Liquid-chromatography mass spectrometry  
Liquid-chromatography mass spectrometric (LC-MS) analysis of proteomic 
EV-content was performed by Ruben Spohrer and Prof. Dr. Stefan Tenzer at 
the Core Facility for Mass Spectrometry, University Medical Centre, Mainz, as 
previously described (Distler et al., 2014; Sielaff et al., 2017). For the purity 
analysis of differentially prepared EV samples, the mean scores (parts per 
million of total proteins) of ApoA1, complement component 3 (CoC3), 
immunoglobulin κ light chain (IGK) and albumin were compared to EV 
associated markers CD81 and Syntenin. 
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2.6 Statistical analysis 
Marker fold-changes obtained from EV Array, WB and MACSPlex analysis 
were statistically analyzed in JMP. Log base-2 normalized values were 
compared by ANOVA across the three time points in the exercise setting (pre 
exercise, RQ 0.9 and post exercise). A significant global F-test (p<0.05) was 
followed by a post-hoc test using each pair’s student’s t-test. Post hoc p-values 
were Bonferroni-Holm-corrected for the comparison ‘pre to RQ 0.9’ and ‘pre to 
post’ and a value of < 0.05 was considered significant (*=p<0.05, **=p<0.01, 
***=p<0.001). Marker fold changes were transformed back and are presented 
in diagrams as geometric means with individual subject results for WB analysis 
and 95 % confidence intervals for EV Array and MACSPlex analysis. Full list 
including geometric mean fold changes, 95 % confidence interval and 
Bonferroni-Holm corrected post hoc p-values in tbl. S2 to S4. 
The heatmaps of MACSPlex marker fold-changes were generated in R 
(version 3.5.0) with the ComplexHeatmap package (version 1.18.1), clustering 
was done with Pearson correlation (Gu et al., 2016). 
42 
 
3 Results 
3.1 Evaluation of EV-isolation from human blood plasma 
3.1.1 EV isolation based on size exclusion chromatography 
Identification of EV-rich SEC fractions 
Isolation of EVs from blood plasma can be performed based on different EV 
characteristics. Using size exclusion chromatography, EV enrichment is 
dependent on their size and interaction with a column matrix which is different 
for other plasma components. Here, plasma was subjected to SEC on self-
made sepharose columns (see chapter 2.4.2) and EV-rich SEC fractions were 
defined using NTA, protein measurement and WB. Comparison of particle 
numbers and protein concentration indicates that fractions 4 to 6 are particle-
rich while protein-poor (a representative result is shown in fig. 3.1 a). An 
increasing amount of protein was detected in fractions 7 to 10 which was also 
visible in NTA measurement by increasing light scattering due to the sample’s 
background (see fig. S1). Particle-rich fractions 4 to 6 revealed a characteristic 
size distribution for small EVs with mean particle sizes of 107.9 nm (#4), 102.7 
nm (#5) and 98.8 nm (#6) (fig. 3.1 b). WB analysis indicated presence of the 
vesicular marker proteins CD9, CD81 and CD63 and the platelet-EV marker 
CD41b in fractions 4 to 7 (fig. 3.2 a). ApoA1 protein was slightly detectable in 
fraction 6 and strongly increasing in fractions 7 to 10, indicating co-isolation of 
HDL. Additionally, unspecific binding in WB was increasing in comparable 
extend to the protein amount detected by BCA (fig. 3.1 a) and ponceau staining 
(fig. 3.2 b), most probably induced by the massive presence of albumin (65-
70 kDa) and other plasma proteins in the later fractions. Finally, in favor of EV 
purity, fractions 4 to 6 were considered EV-rich while protein-poor and used 
for further analysis of EVs. 
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Figure 3.1: Identification of EV-rich SEC fractions I. (a) NTA (bars) and protein 
content (line) of SEC fractions. Bar graphs indicate mean particle number from one 
experiment, error bars indicate technical variation of NTA measurement. (b) Size 
distribution of particle-rich SEC fractions.  
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Figure 3.2: Identification of EV-rich SEC fractions II. (a) WB analysis of SEC 
fractions using EV associated markers (CD9, CD63, CD81), a platelet specific marker 
(CD41b) and apolipoprotein A1 (ApoA1) as lipoprotein marker. Fractions 4 to 6 
(=SEC-EVs) are considered EV-rich while plasma protein- and lipoprotein-poor. (b) 
Ponceau staining of single SEC fractions subjected to SDS-PAGE.  
Characterization of “SEC-EVs” 
To characterize EVs purified by SEC in further analyses, pooled SEC fractions 
4 to 6 were concentrated 30-fold by UF, defined as SEC-EVs and subjected to 
EM, NTA and WB. EM imaging revealed enrichment of vesicular structures in 
the size range of small EVs (fig. 3.3 a). Though, smaller non-EV structures 
were also detected, possibly indicating co-isolation of lipoprotein subclasses. 
Additionally, aggregation of EVs was visible which could be due to the isolation 
process or caused during sample storage or preparation for EM analysis. In 
NTA of SEC-EVs, a characteristic size profile of small EVs was observed (fig. 
3.3 b). Mean particle size was 106.3 nm and particle concentration was 
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measured as 7.3 x1010 particles/ml plasma. These characteristics were 
reproducible and not influenced by the exercise intervention (see chapter 
3.3.1). Importantly, estimation of particle size and concentration may not reflect 
actual EV size and concentration which will be addressed later (see chapter 
3.3.1).  
Marker analysis by WB of SEC-EVs confirmed marker presence of vesicular 
markers CD9, CD63 and CD81 and the platelet-EV marker CD41b (fig. 3.4 a). 
Additionally, vesicular markers TSG101 and Syntenin could be detected in the 
enriched SEC-EVs. Furthermore, staining for the membrane protein Na/K-
ATPase was positive. As expected, lipoprotein co-isolation was not completely 
abolished which is reflected by presence of ApoA1 bands. Also, plasma 
proteins like albumin are still contained in the EV sample indicated by strong 
signals in ponceau staining (fig. 3.4 b). Interestingly, Alix, heat shock protein 
(HSP)70, and flotillin-1 (Flot1) which were previously shown to be present in 
plasma ExerV isolations (Frühbeis et al., 2015) were not detectable in SEC-
EVs (data not shown). Though WB signals, except from ApoA1, are generally 
lower in plasma EV samples at rest, no markers appeared only after exercise 
intervention (see chapter 3.3.2). Next, SEC-EVs were analyzed with LC-MS in 
a pilot experiment which revealed strong co-isolation of non-EV components 
(fig. 3.4 c). CD81 and Syntenin were only marginally detected and markers 
such as CD63, Alix and TSG101 were absent. Apolipoproteins (e.g. ApoA1), 
proteins of the complement system (e.g. CoC3), immunoglobulins (e.g. 
immunoglobulin κ light chain) and albumin were found in roughly 50- to 5,000-
fold higher proportion than the EV-associated markers. Therefore, SEC-EV 
samples need to be further purified for LC-MS assessment of markers 
incorporated within the membranes or the lumen of ExerVs. Taken together, 
the implemented SEC strategy leads to enrichment of EVs from blood plasma 
exhibiting characteristics of small EVs. SEC-EVs can successfully be used in 
EM and WB analysis, while further purification is necessary to implement 
sensitive proteomic analysis. 
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Figure 3.3: EM and NTA characterization of plasma-derived SEC-EVs. (a) 
Transmission electron microscopy image of SEC-EVs. Scale bar refers to 200 nm. (b) 
Representative NTA size distribution profile of SEC-EVs.  
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Figure 3.4: Proteomic characterization of plasma-derived SEC-EVs. (a) WB 
characterization of SEC-EVs using genuine EV-markers, CD41b and ApoA1. (b) 
Ponceau staining of SEC-EVs separated in SDS-PAGE. (c) LC-MS purity analysis of 
SEC-EVs by evaluating ApoA1, complement component 3 (CoC3), immunoglobulin 
κ light chain (IGK), Albumin and EV-associated marker proportion. ppm = parts per 
million.  
SEC isolation from K562 cell culture supernatant 
To improve knowledge on the method of SEC using less complex sample 
material, EVs were purified from the cell culture supernatant of the 
myelogenous leukemia cell line K562. EVs were pre-enriched using UF of 
conditioned CCS (protocol P1 or P2, see chapter 2.3.1) and further isolated by 
SEC of the UF-concentrated CCS (P1). For the experiment depicted in fig. 3.5 
and 3.6, EVs derived from 3.15 x107 K562 cells within 24 h were loaded on the 
SEC column. The ultrafiltrate as well as pooled SEC fractions 3+4, 5+6 and 
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7+8 were analyzed in NTA and WB. UF-enriched EVs as well as SEC #5+6 
revealed characteristic particle size distributions with mean particle sizes of 
181.4 nm and 175.6, respectively (fig. 3.5 a). Concentration of UF-EVs was 
6.5 x108 particles/ml CCS while SEC #5+6 had a reduced particle 
concentration of 2.1 x108/ml CCS (fig. 3.5 b). The pooled fractions 3+4 and 
7+8 showed even lower particle concentrations around 0.5 x108/ml CCS. This 
overall course of SEC fractions in NTA was reproducible (see chapter 3.1.3, 
fig. 3.9). In WB analysis, SEC fractions #5+6 and #7+8 revealed markers of 
small EVs with positive staining for CD9, CD81, CD63, and Syntenin (fig. 3.6). 
 
 
Figure 3.5: NTA of EVs isolated from K562 CCS. (a) Size distribution and (b) 
concentrations in cell culture supernatant (CCS) of UF-EVs and combined SEC 
fractions measured in NTA. Error bars indicate technical variation (SEM) of NTA 
measurement of one sample. 
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Additionally, HSP70, which was not detectable in plasma SEC-EVs, was 
visible in #7+8 possibly indicating that elution of free or vesicle-bound HSP70 
is restricted to later SEC fractions. All analyzed markers were also detectable 
in UF-EVs though a clear enrichment in CD63 and CD81 became obvious in 
SEC #5+6 in comparison to UF-EVs. Furthermore, the EV-associated markers 
TSG101 and Flot1 are rarely detectable in UF-EVs while not detectable in 
SEC-EVs, which might be due to low marker concentrations on the EVs. The 
endoplasmic reticulum-associated protein Calnexin is also only visible in UF-
EVs indicating efficient removal of remaining cell debris by SEC. These 
findings indicate that SEC is an efficient method to further enrich EVs from UF-
EVs, though sample purity might be accompanied by loss of EVs resulting in 
less detectable markers in WB analysis and a lower particle concentration in 
NTA. Still, the implementation of SEC for K562-derived EVs confirmed the 
observations made for SEC of blood plasma EVs. 
 
 
Figure 3.6: WB analysis of EVs isolated from K562 CCS. WB characterization of 
combined SEC fractions using genuine EV-markers and non-EV markers. UF-EVs 
and SEC #5+6 EVs were loaded in the same particle amount (NTA) of 3 x109/lane. 
The other samples were adjusted for volume. 
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3.1.2 Enrichment of EV subpopulations using immuno-affinity capture 
Characterization of immuno-affinity captured EVs 
An alternative method to purify EVs from blood plasma, is the isolation of EV 
subpopulations using magnetic beads coupled to antibodies specific for EV-
associated marker proteins. Here, a commercial kit with antibodies against the 
tetraspanins CD9, CD63 or CD81 was utilized (see chapter 2.4.5).  
WB analysis revealed that the EV markers CD9, CD63, CD81, Syntenin, and 
CD41b are detectable in CD9+-, CD63+-, and CD81+EVs (fig. 3.7 a). Several 
of the markers were previously detected in SEC-EVs. No signals were 
observed for TSG101 in each of the three subpopulations. Consistently, CD9, 
CD63, and CD81 showed the strongest signals in the isolation with the 
respective antibody (example on fig. 3.7 a: same blot, same sample amount, 
same exposure time). This might indicate that the isolations are specifically 
enriching EV subpopulations. Furthermore, CD9+EVs displayed the strongest 
signals for CD41b. Membrane marker Na/K-ATPase was not detectable in 
plasma samples taken at rest but were found in samples taken after exercise, 
while Calnexin was undetectable (not shown). Taken together, the use of 
immuno-affinity capture enables efficient isolation of CD9+-, CD63+-, and 
CD81+ EV subpopulations from human blood plasma. 
WB analysis further demonstrated that also non-EV components are eluted in 
the CD9+-, CD63+-, and CD81+EV samples. Ponceau staining (fig. 3.7 b) 
revealed a prominent band at ~70 kDa most probably caused by co-isolated 
albumin, but overall co-isolation of plasma proteins seems to be reduced 
compared to SEC-EVs. Importantly, no HDL was co-isolated which is indicated 
by negative ApoA1 staining, except from very few samples (not shown). 
However, the secondary anti mouse antibody lead to staining of the light chain 
(~25 kDa) and the heavy chain (~50 kDa) of the isolation antibody in CD9+- 
and CD63+EVs. Additionally, unspecific bands at ~75 kDa (CD9+EVs) and 
~100 kDa (CD9+- and CD63+EVs) were visible which could be reduced via 
heating of the sample prior to SDS-PAGE (not shown). These might result from 
still linked antibody heavy and light chains or their dimers. Additionally, the 
magnetic beads which are used for separation of EVs from plasma remain in 
the EV samples (visible in SDS-PAGE as brown sediments remaining in the 
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gel pockets). This excludes subsequent size and concentration analysis of 
bead-isolated EVs by NTA. Conclusively, though lipoprotein and plasma 
protein co-isolation seems to be reduced in immuno-affinity isolated EVs 
compared to SEC-EVs, also non-EV components are eluted in the CD9+-, 
CD63+-, and CD81+EV samples which affect certain downstream analyses. 
 
 
Figure 3.7: Characterization of immuno-affinity captured plasma EVs. (a) WB 
characterization of CD9+EVs, CD63+EVs and CD81+EVs using genuine EV-markers 
and CD41b. (b) Ponceau staining of CD9+EVs, CD63+EVs and CD81+EVs separated 
in SDS-PAGE. 
Modification of immuno-affinity capture 
To further increase the purity of immuno-affinity captured EVs, removal of the 
magnetic beads from the isolated EVs is necessary. To this end, CD63+EVs 
were lysed directly on the column and recovered in the applied lysis buffer, 
instead of eluting EVs from the column detached from the magnetic device 
with PBS. In this case, beads remained at the magnetic device reflected by a 
colorless eluate and absence in SDS-PAGE gel pockets. Using WB analysis, 
the different protocols were compared, using plasma samples from a non-
exercise setting (n=3). Interestingly, direct lysis at the magnet lead to 
increased band intensity of CD9, CD63, CD81, Syntenin, as well as CD41b 
(fig. 3.8 a). Proportion of the marker intensities between the individual samples 
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(1 to 3) remained similar indicating proper EV isolation. However, also 
Calnexin was detectable though being absent in the EV samples isolated 
according to the standard protocol. To increase EV concentration, it was tested 
weather the first drop of the eluate can be discarded since EV elution was 
expected to occur later. However, there were considerable marker intensities 
in WB analysis of the collected first drop of lysed EVs.  
 
 
Figure 3.8: Modification of immuno-affinity capture of plasma EVs. (a) WB 
analysis of CD63+EVs, derived from 3 different samples from a non-exercise setting 
(samples 1 to 3), captured following the manufacturer’s instructions (standard) or by 
direct lysis at a magnetic device. (b) CD63 and CD9 staining in WB of lysed 
CD63+ExerVs (same sample volume loaded). (c) Purity analysis of lysed 
CD63+ExerVs by LC-MS. ppm = parts per million. 
 
LC-MS analysis was further applied to estimate the purity of CD63+EV 
samples. These were derived from an exercising subject at rest, immediately 
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after exhaustion and 2 h after completion of the test, which was performed as 
described above (see chapter 2.2). Though immuno-affinity capture possibly 
was impaired due to aggregation of magnetic beads, which was visible as 
brown precipitation in the tube, WB analysis revealed proper detection of the 
tested markers CD9 and CD63 (fig. 3.8 b). However, co-isolation of non-
vesicular components was comparable as in SEC-EVs with high plasma 
protein contamination (LC-MS analysis, fig. 3.8 c). Thus, further improvements 
of the isolation process need to be implemented to prepare immuno-bead 
isolated EVs for proteomic analysis. Taken together, immuno-affinity capture 
is an efficient method to enrich CD9+-, CD63+-, and CD81+EVs from human 
blood plasma. Magnetic beads can be detached from the EVs by direct lysis 
of the EVs at the magnetic device. This approach may further increase EV 
concentration. Additional improvements of the isolation protocol will further 
increase EV-purity to perform more sensitive downstream characterization like 
proteomic analysis. 
3.1.3 Highly pure recovery of blood plasma EVs 
In order to increase the purity of isolated plasma EVs, multiple consecutive 
steps of EV enrichment including SEC, UF, iodixanol density gradient (IDG) 
centrifugation and UC were implemented. The established experimental 
setting by Vergauwen et al. (unpublished) was transferred to our laboratory 
(fig. 3.9 a) to validate the isolation procedure. SEC-EVs of 12 ml plasma 
derived from a healthy volunteer who performed an incremental exercise test 
until exhaustion on a treadmill were recovered as described above. 
Subsequently, SEC-EVs were concentrated to a final volume of 0.5 ml and 
loaded onto the top of the IDG. After centrifugation, 2 ml of pooled IDG 
fractions were purified by SEC to remove iodixanol. NTA of pooled IDG 
fractions after SEC revealed characteristic size distributions for each of the 
analyzed fractions except from #10+11 (fig. 3.9 b) with mean particle sizes of 
127.1 nm (#1-3), 129.1 nm (#4+5), 123.2 nm (#6+7), and 123.2 nm (#8+9). 
Highest particle concentrations (fig. 3.9 c) were measured in IDG #6+7 
(1.7 x1010 particles/ml plasma) and #8+9 (2.9 x1010 particles/ml plasma). Also, 
IDG #1-3 exhibited a considerable particle concentration of 1.3 x1010 
particles/ml plasma supposedly attributed to the presence of lipoprotein 
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subclasses which was supported by the appearance of a yellow ring in the 
gradient after centrifugation (not shown). WB analysis of IDG fractions 
confirmed vesicle presence in particle-rich fractions by the presence of CD9, 
CD63, CD81, and CD41b (fig. 3.9 d). Interestingly, while stronger bands for 
CD9 and CD81 were visible in #6+7, CD41b was only detectable in #8+9. 
However, a band which might be attributed to Calnexin staining was visible in 
#8+9 though not at the exact molecular size. ApoA1 staining was negative for 
each of the samples (not shown). However, impaired functionality of the 
antibody cannot be excluded in this case since #1-3 were expected to be 
positive for the HDL marker ApoA1. Summarized, this isolation approach 
resulted in the identification of possibly four EV-rich fractions which might be 
separated from the lipoprotein-rich fractions. 
 
Figure 3.9: Combination of EV isolation strategies: plasma EVs. (a) Overview of 
the combined isolation strategy. (b, c) NTA size profiles and particle concentrations 
of SEC-purified IDG fractions. Bar graphs indicate mean particle number from one 
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experiment, error bars indicate technical variation of NTA measurement. (d) WB 
analysis of SEC-purified and pelleted IDG fractions. 
In a next step, vesicular content of IDG fractions 6 to 9 were analyzed in more 
detail. To this end, the purification strategy described above was repeated with 
pre and post exercise SEC-EVs isolated from the plasma of a subject who had 
accomplished the standard incremental cycling test until exhaustion (see 
chapter 2.2). Vesicular markers CD81, Syntenin and CD41b exhibited the 
strongest intensities in WB analysis in IDG fractions 8 and 9 (fig. 3.10 a).  
 
 
Figure 3.10: Proteomic content of EVs isolated with combined isolation 
approach. (a) WB analysis of SEC-purified and pelleted IDG fractions derived from 
pre (left) and post (right) exercise plasma. (b) LC-MS purity analysis of SEC-purified 
and pelleted IDG fractions by estimation of ApoA1, CoC3, IGK and Albumin co-
isolation with EV-associated markers CD81 and Syntenin. ppm = parts per million. 
 
However, marker distribution seems different from the previously described 
distribution (fig. 3.9 d) with a shift of vesicular content to later fractions. Also, 
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ApoA1 and Calnexin were found in the fractions enriched in EV markers while 
fractions 1-3, again, were free of ApoA1. Additionally, a strong unspecific band 
appeared in the fractions positive for EV-associated markers. LC-MS analysis 
of fractions 7 to 9 was performed to assess the purity of the EVs. An elevation 
of Syntenin and CD81 was confirmed in fractions 8 and 9 compared to fraction 
7. Though, the presence of ApoA1 and other plasma components indicated 
poor purity of EV samples (LC-MS analysis, fig. 3.10 b). Conclusively, a 
relevant enhancement of ExerV purity could not be achieved. However, the 
approach needs to be repeated to exclude technical reasons like improper 
gradient preparation or sample recovery from the gradient after overnight 
centrifugation. 
EVs from K562 CCS were analyzed in parallel to confirm purification of EVs 
via the depicted strategy. To this end, EVs derived from 4 x107 cells within 24 h 
were enriched by SEC. Fractions 5 to 7 were concentrated to 0.5 ml, loaded 
on the IDG and processed as described above. Though particle concentration 
of UF-EVs and SEC-EVs was comparable to previous isolations (fig. 3.11 a, 
b), NTA of IDG fractions did not result in measurable particle concentrations. 
However, WB revealed a weak presence of CD63 in IDG fractions #6+7 
(fig. 3.11 c). Conclusively, WB analysis is in line with the first results for plasma 
EVs, although K562 EV sample material has to be increased for further 
observations. 
Taken together, after further modification of the isolation protocol, combination 
of SEC and IDG might offer the possibility to increase the purity of EVs. These 
may be used in sensitive downstream analysis like RNA-seq or proteome 
analysis. 
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Figure 3.11: Combination of EV isolation strategies: K562 CCS. (a, b) Size 
distribution as well as concentrations of UF-EVs and combined SEC fractions. Bar 
graphs indicate mean particle number from one experiment, error bars indicate 
technical variation of NTA measurement. (c) WB characterization of UF-EVs and EVs 
enriched using the combined isolation approach. 
3.2 Exercise study design for the analysis of ExerV 
To study the release kinetics and the origin of EVs under exercise conditions, 
21 healthy male athletes were subjected to an incremental cycling test until 
exhaustion. The study participants had an average age of 28.7 ±4.2 years and 
a BMI of 22.8 ± 2.0. Analysis of blood parameters did not show aberrations 
from the normal range. Several performance diagnostic parameters like O2-
consumption, lactate levels, cfDNA concentration and heart rate were 
monitored during the test and displayed stepwise elevation until exhaustion 
(tbl. 3.1). Lactate and cfDNA levels remained constant at reduced workloads 
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and increased strongly after the individual anaerobic threshold (exemplified for 
one study participant in fig. 3.12). Time points for EV analysis were prior to the 
exercise (pre), during the test at a respiratory quotient (RQ) of 0.9 and 
immediately at the end of the exercise (post). The average time until an RQ of 
0.9 was 14 ±3.7 min and the mean load was 201 ±52.9 Watt. The average time 
until the end of the test was 23.6 ±2.8 min and the participants reached a mean 
of 324.3 ±49.5 Watt at exhaustion. ExerV kinetics (see chapter 3.3) and origin 
(see chapter 3.4) were examined based on data obtained from EV analysis in 
blood plasma or differentially isolated EVs. To this end, a comparative 
experimental set-up was implemented as illustrated in fig. 3.13 and included 
EV isolation by SEC and immuno-affinity capture and EV analysis via EV 
Array, MACSPlex, WB, NTA, and IF. Due to the restriction in the sample 
volume taken at each point of analysis (see chapter 2.2.4), EV characterization 
was not performed with each of the analysis strategies at all time points in 
parallel. However, the accumulation of EV data from multiple subjects, EV 
subclasses and examination methods (see tbl. S1) allows a detailed 
characterization of ExerVs.  
 
 
Figure 3.12: Characterization of the implemented cycling exercise setting. 
Illustration of a representative incremental cycling exercise test and the time points of 
EV analysis. Blood lactate (line) and cell-free DNA levels (cfDNA; bars) were 
measured every three minutes at increasing workloads. The individual anaerobic 
threshold (IAT) is indicated by a dashed vertical line. Venous blood was drawn prior 
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to the test (pre), during the exercise at a RQ of 0.9 and at the end of the test (post). 
Error bars indicate technical variation of cfDNA measurement. 
Table 3.1: Test parameters of the cycling exercise study subjects  
 time 
(min) 
load 
(Watt) 
load/ 
weight 
(Watt/kg) 
Borg 
lactate 
(mmol/l) 
cfDNA 
(ng/ml) 
heart 
rate 
(1/min) 
VO
2
 
(ml/min 
/kg) 
IAT 
(Watt) 
pre - - - - 
0.9 
(0.2) 
25 
(11.9) 
80.2 
(14.4) 
5 
(1.1) 
197.8 
(49.4) 
RQ 
0.9 
14 
(3.7) 
201 
(52.9) 
2.7  
(0.7) 
14.6 
(2.0) 
2.3 
(1.1) 
45.2 
(25.0) 
145.4 
(16.6) 
33.7 
(6.5) 
post 
23.6 
(2.8) 
324.3 
(49.5) 
4.4  
(0.8) 
19.6 
(0.6) 
9.4 
(2.8) 
163.5 
(90.2) 
184.7 
(8.5) 
48.8 
(6.5) 
Values are given in mean ±SD, n=21 
RQ respiratory quotient, cfDNA cell-free DNA, VO2 oxygen consumption (VO2 at post = 
maximal oxygen consumption), IAT individual anaerobic threshold based on lactate 
accumulations according to Roecker et al., 2003 (Roecker et al., 2003). 
 
 
Figure 3.13: Experimental strategy to characterize ExerVs. Blood cell counts and 
metabolic parameters were evaluated in venous blood which was sampled pre 
exercise, at RQ 0.9 and post exercise. Unprocessed plasma was used for EV analysis 
in imaging flow cytometry (IF) and the EV Array as well as for cfDNA estimation. For 
WB and MACSPlex analysis, EVs were purified from plasma by SEC or immuno-
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affinity capture using CD9-, CD63-, or CD81-magnetic beads. SEC-EVs were 
additionally analysed in nanoparticle tracking analysis (NTA) and IF.  
3.3 EV kinetics during incremental cycling 
3.3.1 Absolute quantification of ExerVs 
To estimate EV concentrations and evaluate ExerV kinetics, EVs were 
analyzed by imaging flow cytometry (IF) and nanoparticle tracking analysis. 
For IF, EVs in plasma were stained with the membrane dye BODYPI and total 
EVs as well as the defined EV subpopulations “exosomes” and “MVs” were 
measured (see chapter 2.5.3). The total EV gate as well as the exosome gate 
in stained plasma samples showed fluorescent events while unstained plasma 
and PBS buffer control were free of fluorescent events (fig. 3.14 a). As 
expected due their small size, some vesicles in the exosome gate were only 
detectable in fluorescent mode but not in SSC mode (fig. 3.14 b, lower part). 
Measurement of ExerV kinetics in the plasma of two subjects indicated 
exosome numbers starting at 1.9 and 1.5 x108/ml plasma both increasing to a 
concentration of 2.2 x108/ml plasma at RQ 0.9 and decreasing to 
concentrations of 1.8 and 1.3 x108/ml plasma post exercise (fig. 3.14 c). MV 
kinetics followed the same trend starting at 1 and 0.7 x108/ml plasma evenly 
increasing to a concentration of 1.3 x108/ml plasma at RQ 0.9 and decreasing 
to concentrations of 1 and 0.7 x108/ml plasma post exercise. This summed up 
in total EV kinetics starting at 2.9 and 2.2 x108/ml plasma increasing to 
concentrations of 3.6 and 3.5 x108/ml plasma at RQ 0.9 and decreasing to 
concentrations of 2.9 and 2 x108/ml plasma post exercise. To further evaluate 
EV concentration changes in isolated ExerVs, SEC-EVs of seven subjects 
were analyzed in NTA. Particle size distribution of EVs was as described above 
(fig. 3.15 a, also see 3.1.1). Particle concentrations at rest varied between 
8.1 x109 and 1.3 x1011/ml plasma, at RQ 0.9 between 9.9 x109 and 1.9 
x1011/ml plasma and post exercise between 5.9 x109 and 3.4 x1011/ml plasma 
(fig. 3.15 b). Interestingly, measured EV numbers were 2 to 3 orders of 
magnitude higher than in IF analysis. Calculation of mean fold changes at RQ 
0.9 (0.97-fold) and post exercise (1.03-fold) compared to pre exercise revealed 
no difference in particle concentration (fig. 3.15 c). These observations 
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suggest no (NTA) or only a very short (IF) increase in EV numbers during 
exercise and a reduction to baseline at exhaustion. This is in contradiction to 
the results of earlier studies of the release kinetics of EVs during exercise in 
our group (Frühbeis et al., 2015).  
 
Figure 3.14: ExerV concentrations and kinetics - imaging flow cytometry. (a, b) 
Gating strategy and exemplified events of EVs in imaging flow cytometry. Exos = 
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exosomes/small EVs, MVs = total EVs minus small EVs. (c) Concentration and 
dynamics of BODYPI-stained plasma EVs and their subclasses of two study subjects 
pre, at RQ 0.9 and post exercise (S1, S2). 
 
However, recent publications demonstrated that flow cytometry as well as 
nanoparticle tracking analysis is confounded by the strong presence of 
lipoproteins in plasma as well as isolated EVs (Jamaly et al., 2018; Sodar et 
al., 2016). 
 
 
Figure 3.15: ExerV concentrations and kinetics - nanoparticle tracking analysis. 
(a) Exemplified NTA size profiles of SEC-EVs collected pre, at RQ 0.9 and post 
exercise. (b, c) Total NTA particle counts and fold changes in SEC-EVs during the 
exercise setting (geometric mean, SEM, n=7). 
 
To further reveal details of the characteristics of NTA and IF of plasma EVs, 
single SEC fractions retrieved from the plasma samples of one study subject 
were either measured in NTA or stained with BODYPI and measured in IF. No 
change in EV numbers was detected in IF or NTA of the SEC-fractions during 
exercise and, again, EV numbers in NTA analysis were several orders of 
magnitude higher than in IF analysis (fig. 3.16). Furthermore, the EV-rich 
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fractions 4 to 6 identified by WB and NTA of single SEC-fractions before (see 
fig. 3.1) seem particle-low in IF analysis compared to fractions 7 and 10, which 
in turn showed reduced (#7) or no presence (#10) of EV markers in WB 
analysis. This was observed for each of the subpopulations analyzed in IF and 
was reproduced in analysis of SEC-fractions recovered from the subject’s 
plasma after one freeze-thaw cycle (not shown). In light of the current literature 
(Jamaly et al., 2018; Sodar et al., 2016), these findings might indicate that 
different factors including different lipoprotein subclasses are confounding 
NTA and IF analysis which leads to misinterpretations of the study data. 
Hence, it can be concluded that neither NTA nor IF analysis performed under 
the presented conditions are suitable techniques to depict EV concentrations 
or kinetics during exercise. 
 
  
Figure 3.16: Comparison of NTA and IF to estimate EV concentration in SEC-
fractions. Total NTA particle counts (green) and fluorescent (BODYPI) events (total 
EVs and EV-subclasses) in single SEC fractions. 
3.3.2 Semi-quantitative analysis of ExerV release 
In an alternative approach to visualize ExerV kinetics, exercise-induced 
changes of EV amount was further analyzed by semi-quantitative assessment 
in WB analysis. EV-associated markers were observed to increase in ExerV 
subclasses, normalized to plasma volume, from pre to RQ 0.9 and post 
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exercise (fig. 3.17 and 3.18). In SEC-EVs, significant increases of roughly 2-
fold were observed for the tetraspanins CD9, CD63 and CD81 post exercise, 
which was already evident as slight elevation at increasing exercise intensity 
at RQ 0.9 (fig. 3.18), suggesting a load-responsiveness. For the immuno-
affinity isolated ExerVs this was observed for CD9 and CD63 likewise. 
However, CD81 levels were less intensely increased. The markers TSG101 
and Syntenin, associated with late endosome-derived small EVs, showed a 
trend to rise in response to exercise, though fold changes were not significant. 
On the contrary, ApoA1, which reflects lipoprotein co-isolation, remained 
unaffected in SEC-EVs during exercise. Taken together, WB analysis of ExerV 
subclasses suggests an elevation of the EV amount of roughly 2-fold in 
response to the applied exercise setting. This finding was validated for CD9-, 
CD63- and CD81-carrying EVs, possibly including MVs, while quantification of 
exercise-mediated effects on late endosome-derived small EVs need to be 
analyzed in more detail. 
 
 
Figure 3.17: EV marker analysis of ExerVs. WB characterization of SEC-EVs, 
CD9+EVs, CD63+EVs and CD81+EVs derived from exercising subjects using genuine 
EV-markers CD9, CD63, CD81, Syntenin and TSG101 as well as HDL marker ApoA1.  
▪ RESULTS ▪ 
65 
 
Figure 3.18: Semi-quantitative analysis of ExerV kinetics. Densitometric 
quantification of signals derived from WB analysis of the exercising subjects. 
Individual (circle) and mean (bar) fold changes of WB markers. RQ 0.9 and post 
expressed in relation to pre exercise (dashed line). Bonferroni-corrected students 
t-test, n=3-11, *=p<0.05, **=p<0.01, ***=p<0.001. 
3.4 Origin of ExerVs 
3.4.1 Multiplexed marker analysis of ExerVs – EV Array 
To determine the cellular sources of EVs, liberated in response to the applied 
exercise setting, first, EV Array technology was implemented. This multiplex 
assay enables examination of the presence of several markers, including EV 
markers and cell surface markers, via an antibody-mediated detection 
approach (Jorgensen et al., 2013). Plasma samples of ten subjects were 
analyzed in the EV Array and intensity changes in response to exercise were 
observed for a variety of markers (fig. 3.19 a). Alix, CD14, CD142, HLA-ABC 
(MHCI), ICAM-1, LAMP-1 (lysosomal-associated membrane protein 1), and 
tPA (tissue plasminogen activator) displayed a significant elevation from pre 
exercise over RQ 0.9 to post exercise (fig. 3.19 b). Increases of these markers 
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indicated endosomal characteristics and a possible origin of ExerVs from 
endothelial cells and leukocytes. Strikingly, the tetraspanins CD9, CD63, and 
CD81 which were demonstrated to increase in WB analysis (see chapter 
3.3.2), were below the detection threshold of the assay. This was also 
observed for Flot1, HSP70, and CD41b previously described to be released 
within EVs during exercise (Frühbeis et al., 2015). These findings suggest that 
the analysis of EV marker changes in the implemented exercise setting with 
EV Array methodology may be limited. Separation of EVs from the complex 
sample material blood plasma may be crucial to identify further phenotyping 
markers of ExerVs. 
 
 
Figure 3.19: Marker profile of plasma-EVs analyzed in EV Array. (a) Heatmap 
visualization of marker changes during exercise. Markers depicted were higher than 
the LOD in more than 50 % of cases. (b) Mean fold changes of significantly increasing 
markers. 95 %-confidence intervals (CI) depicted. Individual values of biological 
replicates in fig. S2 and S3. Bonferroni-corrected students t-test, *=p<0.05, **=p<0.01, 
***=p<0.001, n=10.  
3.4.2 Cell type specific WB analysis of ExerVs  
Origin of ExerVs from the cellular sources platelets, muscle, and liver, was 
investigated in WB analysis of isolated SEC-EVs, CD9+EVs, CD63+EVs, and 
CD81+EVs.  
CD41b, which is representative for platelet-derived EVs, was found to be 
increased during exercise in all four ExerV subclasses (fig. 3.20 a). Mean fold 
changes were ranging from 1.4- to 3.9-fold at RQ 0.9 and from 2.4- to 8.7-fold 
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post exercise (fig. 3.20 b). While at RQ 0.9 level this increase was only 
significant in CD81+EVs (2.9-fold, p<0.05), significant fold changes post 
exercise were found in CD81+EVs and SEC-EVs (8.7-fold and 2.4-fold, 
p<0.01). These findings strongly indicate a contribution of platelet-derived EVs 
to the pool of ExerVs in the applied exercise setting.  
 
 
Figure 3.20: Platelet-specific WB analysis of ExerVs. (a) WB of CD41b in SEC-
EVs, CD9+EVs, CD63+EVs and CD81+EVs derived from exercising subjects. (b) 
Densitometric quantification of CD41b signals. Individual (circle) and mean (bar) fold 
changes of WB markers. RQ 0.9 and post levels are displayed in relation to pre 
exercise (dashed line). Bonferroni-corrected students t-test, n=2-12, *=p<0.05, 
**=p<0.01, ***=p<0.001.  
 
Further WB analysis of isolated ExerVs did not reveal presence of α-
sarcoglycan (SGCA, fig. 3.21 a, b), which was described to be found in muscle-
derived EVs (Guescini et al., 2015). Likewise, asialoglycoprotein receptor 2 
(ASGPR2, fig. 3.21 c) an indicator for EV release from liver (Conde-Vancells 
et al., 2008), could not be detected. 
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Figure 3.21: Muscle- and liver-specific WB analysis of ExerVs. WB of muscle-EV 
marker α-sarcoglycan (SGCA) in CD9+EVs, CD63+EVs and CD81+EVs (a) and SEC-
EVs (b) derived from exercising subjects. *=unspecific albumin binding. (c) WB 
staining of liver-EV marker asialoglycoprotein receptor 2 (ASGPR2) in SEC-EVs.  
 
Summarized, the previously described exercise-induced release of EVs by 
platelets (Chaar et al., 2011; Frühbeis et al., 2015; Rakobowchuk et al., 2017; 
Wilhelm et al., 2016) was confirmed for SEC-ExerVs and immuno-affinity 
captured ExerVs, but there was no evidence for the release of ExerVs from 
muscle or liver. 
3.4.3 Multiplex bead-based cell surface marker analysis of ExerVs - 
MACSPlex 
To reveal further information about the cellular origin of ExerVs, the 
commercial multiplex bead-based analysis MACSPlex was implemented. The 
platform enables the examination of 37 cell surface markers in an EV-sample 
in parallel. The analysis is based on EV-capture by beads carrying antibodies 
for cell surface markers and subsequent detection with antibodies for the EV-
associated markers CD9, CD63 and CD81, conjugated to APC using flow 
cytometry.  
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Surface marker profiles of ExerVs 
Surface marker profiles of the differentially isolated EVs displayed high signals 
for platelet-associated markers (e.g. CD42a and CD62P), for leukocyte 
markers such as CD8 and HLA-DRDPDQ (MHCII), and endothelial markers 
(CD105), next to the genuine EV-markers CD9, CD63 and CD81 (fig. 3.22). 
Compared to SEC-EVs, a higher number of markers with strong mean 
fluorescence intensities (MFI) are found in the profiles of immuno-captured 
EVs (e.g. CD29 and CD49e). CD9, CD63, and CD81 signals were nearly 
completely reduced in the respective immuno-capture, while detection of e.g. 
CD63 in CD81+EVs was successful. This finding may be explained by 
increasing competition for the respective antibody epitopes used for sequential 
isolation, capturing and detection, and was already described by others (Koliha 
et al., 2016; Wiklander et al., 2018). Interestingly, the overall surface marker 
profiles of CD63+EVs and CD81+EVs were observed as markedly similar while 
CD9+EVs exhibited similarities with SEC-EVs (e.g. higher signals for CD62P 
and HLA-DRDPDQ compared to other markers). 
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Figure 3.22: Cell surface marker profiles of ExerV subclasses. Representative 
mean fluorescence intensities (MFI) of markers determined in MACSPlex analysis of 
SEC-EVs (a) as well as immuno-affinity captured CD9+EVs (b), CD63+EVs (c), and 
CD81+EVs (d).  
Comparison of MACSPlex and WB analysis of ExerVs 
To evaluate the capability of the MACSPlex system to resolve ExerV 
dynamics, tetraspanin and CD41b mean fold increases (fig. 3.23) were 
specifically compared with fold changes in WB (see chapters 3.3.2 and 3.4.2). 
Likewise, incremental increases in response to the exercise setting were 
observed for CD9, CD63, CD81, and CD41b in all four ExerV subclasses. 
However, while tetraspanin changes in CD9+ExerVs, CD63+ExerVs, and 
CD81+ExerVs were comparable in the two semi-quantitative approaches, 
reduced values in MACSPlex analysis (1.3-1.6-fold) compared to WB (1.9-2.6-
fold) were detected in SEC-ExerVs. In contrast, CD41b fold changes of 
immuno-affinity captured ExerVs were strongly decreased in the MACSPlex 
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assay. Conclusively, though exhibiting differing extends of marker changes, 
MACSPlex analysis confirms overall EV-kinetics during exercise.  
 
Figure 3.23: Tetraspanin and platelet marker kinetics in ExerV subclasses 
estimated by multiplex bead-based analysis. Mean tetraspanin and CD41b 
elevations with 95%-CI in (a) SEC-EVs (n=9), (b) CD9+EVs (n=5), (c) CD63+EVs (n=7) 
and (d) CD81+EVs (n=9). Bonferroni-corrected students t-test, *=p<0.05, **=p<0.01, 
***=p<0.001, n=9. 
Identification of the cellular sources of ExerVs 
Next, further analysis of changes in the surface marker intensities in response 
to the applied exercise setting was used for estimation of cellular sources of 
ExerVs. Incremental increases of several cellular markers were observed in 
the individual marker profiles from pre to RQ 0.9 and post exercise (fig. 3.24). 
Also, in heatmap clustering analysis, RQ samples are placed left to the 
respective post samples in almost all cases, though it does not perfectly 
separate RQ 0.9 samples from post samples. Furthermore, ExerVs specifically 
carry markers of lymphocytes (CD4 and CD8), endothelial cells (CD31, CD105 
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and CD146), AP cells (MHCII and CD40), and platelets (CD41b, CD42a, and 
CD62P). While the exposed marker fold-changes in SEC-EVs again remained 
moderate (fig. 3.24 a), higher fold changes were detected in immuno-captured 
EVs (fig. 3.24 b-d). Consistently, the ExerV-subclasses carrying CD4 
(lymphocytes) and CD14 (monocytes) were at a detection minimum at rest, 
but exhibited robust signals after exercise, which is reflected by high fold 
changes for these two markers. In addition to the identification of ExerV-
sources in the individual study participants, low-responders (e.g. S3 and S5) 
and high-responders (e.g. S19 and S23) may be defined. 
Significant mean marker increases were strikingly similar between SEC-, 
CD9+-, CD63+- and CD81+ExerVs (fig. 3.25). The surface markers showed a 
trend to increase at RQ 0.9 as well as significant mean fold increases post 
exercise, which is in in line with the statistics for the release kinetics observed 
in WB (see chapter 3.3.2). Overall, mean fold changes were ranging from 1.2- 
to 5.5-fold (SEC-EVs), 1.2- to 7.5-fold (CD9+EVs), 1.4- to 10.4-fold 
(CD63+EVs), and 1.5- to 9.6-fold (CD81+EVs) post exercise. In SEC-ExerVs, 
CD63+ExerVs and CD81+ExerVs significantly elevated markers specific for 
platelets (CD41b, CD42a, CD62P, from 1.6- to 2.9-fold in mean), lymphocytes 
(CD4, 4.4- to 10.4-fold and CD8, 1.3 to 1.8-fold), and AP cells (MHCII, from 
1.7- to 3.4-fold), as well as MHCI (1.6-to 2.9-fold) were observed. Furthermore, 
the markers CD105 (2.3- to 4.3-fold) and CD146 (2.0- to 3.5-fold), which are 
associated with endothelial cells, increased significantly upon exercise. In 
CD63+ExerVs and CD81+ExerVs also endothelial CD31 (2.5- and 3.7-fold) 
was significantly elevated. In CD9+ExerVs, statistical significance was 
detected for similar but fewer cellular markers, which might be explained by a 
smaller sample size (n=5). Significant marker elevations were likewise 
detected for lymphocyte (CD4, 7.5-fold and CD8, 1.7-fold), endothelial 
(CD105, 3.7-fold, and CD146, 2.4-fold), AP cells (MHCII, 2.3-fold, and CD40, 
2.6-fold), and platelet markers (CD62P, 2.6-fold). CD41b and CD42a 
increases, on the other hand, were not statistically significant. Interestingly, in 
SEC-EVs and CD9+EVs, CD62P exhibited elevated levels (1.5- and 2-fold, 
p<0.05) already at RQ 0.9. Conclusively, phenotyping of SEC- and immuno-
affinity captured ExerVs indicates contribution of platelets, leukocytes 
including lymphocytes as well as monocytes, and endothelial cells to the pool 
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of EVs released into the blood upon exercise. These seem to include CD9+, 
CD63+ and CD81+-subclasses with phenotypes which exhibit only minor 
differences. 
 
Figure 3.24: Individual changes of cell surface markers in ExerV subclasses. 
Heatmap visualization of individual MACSPlex marker increases in SEC-EVs (a) and 
immuno-affinity captured EV subclasses (b-d) including hierarchical clustering for 
markers as well as subjects. Log2-fold changes of MFI at RQ 0.9 and post in relation 
to pre exercise are presented.  
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Figure 3.25: Origin and kinetics of ExerV subclasses. Mean cell surface marker 
elevations with 95%-CI at RQ 0.9 and post normalized to pre exercise in (a) SEC-EVs 
(n=9), (b) CD9+EVs (n=5), (c) CD63+EVs (n=7) and (d) CD81+EVs (n=9). Bonferroni-
corrected students t-test, *=p<0.05, **=p<0.01, ***=p<0.001.   
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4 Discussion 
4.1 ExerVs are a mixture of EVs derived from multiple cell 
populations 
4.1.1 Platelets, endothelial cells, and leukocytes contribute to the exercise-
triggered release of extracellular vesicles into the circulation  
Physical exercise induces broad physiological changes which are 
accompanied by the active release of EVs into the circulation (Frühbeis et al., 
2015; Whitham et al., 2018). It is speculated that these ExerVs are involved in 
the adaptive mechanisms of exercise due to their possibility of acting as long-
distant signaling mediators (Piccirillo, 2019; Safdar et al., 2018). This study 
intended to gain detailed knowledge on small EV release kinetics as well as 
their originating cell populations during acute exercise.  
The phenotyping analysis of ExerVs provides profound insights into the 
composition of small EVs during physical exercise, revealing origin from 
endothelial cells, platelets and leukocytes including lymphocytes, monocytes 
and antigen-presenting cells. Two different multiplexed assays indicated the 
release of vesicles from multiple cell populations. EV Array technology 
analyzing EVs unpurified in blood plasma of exercising humans gave a first 
indication of endothelial and leukocyte origin (fig. 3.19). MACSPlex 
characterization of different ExerV subpopulations, defined by the method of 
isolation via size-exclusion-chromatography, CD9-, CD63- or CD81-immuno 
capture, resulted in a panel of marker proteins found to be significantly 
upregulated in each of the examined EV subpopulations (fig. 3.25). These can 
be assigned to endothelial cells (CD31+, CD105+, CD146+), platelets (CD41b+, 
CD42a+, CD62P+) and leukocytes, including lymphocytic cells (CD4+, CD8+) 
and antigen-presenting cells (MHCII+). EVs generated in response to various 
exercise conditions were considered important players in organ cross-talk and 
long-term adaptive responses triggered by physical activity (Bei et al., 2017; 
Chaturvedi et al., 2015; Frühbeis et al., 2015; Lovett et al., 2018; Safdar et al., 
2018; Whitham et al., 2018). During physical exercise the alteration of a variety 
of physiological processes can be observed, including enhanced 
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cardiovascular signaling, activated immune function and increased 
coagulation capacity (Pedersen et al., 2000; Vanhoutte et al., 2017; Womack 
et al., 2003). This is reflected by elevated levels of ROS, shear forces, 
catecholamines, cortisol as well as cytokines in the circulation immediately 
upon exercise. Conclusively, ExerV phenotyping analysis strongly supports 
the idea that ExerVs contribute to these signaling processes by functioning as 
mediators of endothelial signaling, coagulation processes and immune 
regulation. 
 
Figure 4.1: Origin and putative functions of ExerVs. During physical exercise, 
platelets, endothelial cells, and leukocyte subsets release extracellular vesicles into 
the blood stream. These may function in signaling processes like coagulation, 
angiogenesis and inflammation. 
4.1.2 ExerV subclasses show highly similar release kinetics 
Characterization of four different ExerV subpopulations revealed highly similar 
release kinetics and cellular sources of the ExerV subclasses. In WB and 
MACSPlex analysis ExerVs exhibited consistent marker elevations of more 
than twofold and comparable marker profiles in CD9+EVs, CD63+EVs, 
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CD81+EVs and SEC-EVs (fig. 3.18, 3.20, 3.23, and 3.25). This might indicate 
that overall liberation of the different subpopulations into the circulation is 
triggered by the same release mechanisms. Alternatively, the three 
tetraspanins may be evenly distributed on all ExerVs. Interestingly, more 
detailed comparison of the phenotyping profiles of CD9+EVs, CD63+EVs, 
CD81+EVs and SEC-EVs indicates minor divergences (fig. 3.25). While 
CD63+EVs and CD81+EVs exhibited strikingly similar cell surface marker 
profiles, CD9+EVs and SEC-EVs displayed slight differences including a 
stronger increase in platelet-selectin (CD62P), which already becomes visible 
at RQ 0.9 during exercise. This might indicate a higher proportion of platelet-
derived EVs in CD9+ExerVs and SEC-ExerVs compared to CD63+ExerVs and 
CD81+ExerVs. This is also reflected by stronger CD41b signals in WB analysis 
of CD9+EVs compared to CD63+EVs and CD81+EVs (fig. 3.17). More specific 
information on the composition of ExerVs may be provided utilizing the three 
tetraspanins independently instead of in the combination for EV-detection 
(APC-staining) in MACSPlex. Using MACSPlex assay, different research 
groups characterized the distribution of the tetraspanins in single cell 
populations like HEK-cells, MSCs, B-cells, NK cells and platelets (Koliha et al., 
2016; Wiklander et al., 2018). However, phenotyping of EV subclasses in a 
heterogeneous mixture of EVs in the plasma of exercised subjects appears 
more complex. Isolation of more specific ExerV subpopulations e.g. by 
combining of SEC with IA-capture or by using e.g. CD105-antibodies coupled 
to magnetic beads and subsequent analysis in MACSPlex and WB may further 
shed light on ExerV composition. These findings highlight the multifaceted 
nature of EV mixtures in a complex sample material such as blood plasma and 
the potential of a detailed analysis of several populations of EVs in multiplexed 
assays. 
4.1.3 ExerV release by other cellular populations? 
While our ExerV phenotyping analysis strongly suggests a contribution of 
endothelial cells, platelets and leukocytes, other cells may also release EVs 
upon physical activity. Since muscle cells have a highly increased activity 
during exercise it is considered that they contribute to the pool of ExerVs 
(Guescini et al., 2015; Lovett et al., 2018; Whitham et al., 2018). A recent study 
78 
 
analyzed the proteomic content of EVs after exercise and proposed a model 
of myokine-containing EV release by muscle cells finally taken up in the liver 
(Whitham et al., 2018). However, the analyzed EVs were prepared by low-
speed centrifugation and EV characterization is missing, which impairs the 
actual attribution of cargo to EVs. In our exercise setting, there was no 
evidence of a contribution of muscle cells to the ExerV pool. α-sarcoglycan, 
which was previously described to be released in EVs  1 h after exercise 
stimulation (Guescini et al., 2015), was not detectable in SEC-EVs or immuno-
captured ExerVs (fig. 3.21). Likewise, no contribution of liver EVs to the pool 
of ExerVs could be detected. Though the contribution of other muscle or liver 
cell derived EV populations cannot be excluded, the rapid increase of EVs 
within 15 to 30 min during exercise may rather indicate a release from cells 
which are in direct contact to blood. In line with our ExerV phenotyping, Bryl-
Gorecka et al. (2018) analyzed the proteomic content of ExerVs 1 h after 
completion of an exercise intervention and mainly found proteins associated 
with blood cells or endothelial cells (Bryl-Gorecka et al., 2018). Liberation of 
ExerVs by red blood cells and their precursors should be addressed in future 
studies given the high number of RBCs in blood and the stimulating effect of 
exercise on hematopoiesis (Hu et al., 2012). Furthermore, more detailed 
analysis of the ExerV subpopulations identified in MACSPlex analysis will 
further reveal contribution of more specific cellular sources to the pool of 
ExerVs. Interestingly, CD14, which is prominently expressed on 
monocytes/macrophages, is to a lower extend also expressed on neutrophils 
(Antal-Szalmas et al., 1997). Similarly, CD105 and CD146, which are mainly 
attributed to endothelial cells and EVs, are also found on mesenchymal 
stromal cells and EVs (Börger et al., 2016; Eirin et al., 2016; Lindoso et al., 
2014). These considerations again highlight the complexity of EV mixtures in 
blood and the need for stringent and well-designed EV isolation and 
characterization strategies. 
Taken together, antibody-based semi-quantitative analysis enabled the 
estimation of ExerV dynamics as well as originating cell populations. Further 
analysis addressing more specific ExerV subpopulations may further untangle 
the complex composition of EVs in the plasma of exercising humans to unravel 
their functions in multi-systemic signaling. 
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4.2 Putative functions of ExerVs 
4.2.1 ExerV release by platelets indicates involvement in coagulation 
processes 
Surface marker analysis of ExerVs revealed an incremental release of platelet-
derived EVs into the blood during exercise, which is in line with the literature 
on platelet microparticles. In multiple studies, CD41+, CD42a+ and CD62P+-
platelet-EVs were demonstrated to increase during physical activity, starting at 
an early phase of exertion (Chaar et al., 2011; Frühbeis et al., 2015; 
Rakobowchuk et al., 2017; Schwarz et al., 2018; Sossdorf et al., 2011; Wilhelm 
et al., 2016). Likewise, WB and MACSPlex phenotyping of ExerVs implicated 
the liberation of CD41b+-, CD42a+-, and CD62P+EVs from platelets during 
exercise (fig. 3.20 and 3.25). Furthermore, CD62P+SEC-ExerVs and 
CD62P+CD9+-ExerVs exhibited a considerable increase already at 
submaximal workload. In vitro analyses demonstrated that elevated levels of 
shear stress and subsequent coagulative activity leads to the release of EVs 
by platelets (Miyazaki et al., 1996; Reininger et al., 2006). Furthermore, these 
PMPs exhibited pro-coagulant activity and enhanced thrombus formation. 
During exercise, pro-thrombic as well as fibrinolytic effects can be observed, 
and the fine-tuning of these counter-acting reactions are considered to be an 
adaptational response of regular physical exercise leading to improved blood 
hemostasis (el-Sayed, 1996; Womack et al., 2003). Thus, ExerV-release by 
platelets may be part of a sensitive signaling mechanism to maintain blood 
homeostasis. However, PMPs were also described to promote angiogenesis 
(Italiano et al., 2008; Kim et al., 2004), mediate pro-inflammatory signaling 
(Mause et al., 2005; Vajen et al., 2017) and affect hematopoiesis (Baj-
Krzyworzeka et al., 2002). As reviewed by Boilard et al., EVs assigned to 
platelets may derive from activated platelets or megakaryocytes, can be 
phosphatidylserine positive or negative, and may contain mitochondria 
(Boilard et al., 2015). Further detailed characterization of platelet-derived 
ExerV subtypes or ExerV analysis in patients with coagulopathy or 
thrombophilia may provide deeper insights into the diverse functions of the 
multiple subclasses of platelet-ExerVs. 
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4.2.2 Endothelial cell-derived EV signaling upon exercise 
Elevated levels of endothelial cell markers in several examined ExerV 
subpopulations implies a substantial release of small EVs from endothelial 
cells upon exercise. In MACSPlex analysis, the markers for endothelial cells 
(CD31, CD146 and CD105) were among the most upregulated markers after 
exhaustive cycling (fig. 3.25), indicating a robust secretion of endothelial EVs 
to the bloodstream during exercise. This finding is also supported by EV Array 
analysis (increasing levels of ICAM-I and tPA, fig. 3.19).  
The effect of acute exercise on EV-release by endothelial cells was examined 
by several groups using flow cytometric analysis of endothelial microparticles 
(Lansford et al., 2016; Möbius-Winkler et al., 2009; Shill et al., 2018; Sossdorf 
et al., 2011). In contrast to our work, most of the studies found no or only 
marginal increases of EMPs immediately upon diverse exercise settings 
(including 4 h cycling and marathon running) but increased levels one day 
later. Only Lansford et al. found a doubling of activated CD62E+EMPs after 30 
min of moderate cycling exercise (Lansford et al., 2016). Most of the EMP 
analyses were focused on CD31+ and AnxV-binding EMPs, considered as 
apoptotic EMPs (Wilhelm et al., 2018). These elevated levels of EMPs were 
related to harmful impact on e.g. vascular functions by pro-inflammatory and 
pro-coagulative signaling (Hromada et al., 2017). However, apoptotic 
processes take far longer than 15 to 30 minutes as analyzed in our exercise 
study. Accordingly, CD31+EVs did not respond to exercise in the same extend 
as CD105+ and CD146+EVs in MACSPlex phenotyping analysis (fig. 3.25). 
This finding suggests an early active release of endothelial EVs triggered by 
different mechanisms than apoptosis, which might have a targeted function on 
recipient cells. For example, endothelial exosomes were demonstrated to 
promote tube formation and vessel sprouting in HUVECs (Sheldon et al., 2010) 
and might be associated with angiogenic signaling during exercise. 
Interestingly, Hergenreider et al. showed that in response to increased shear 
stress, HUVEC-EVs are capable of inducing an atheroprotective phenotype in 
smooth muscle cells by transferring miRNA species (Hergenreider et al., 
2012). Conclusively, ExerV phenotyping indicates the immediate and active 
release of small endothelial EVs during a short bout of exhaustive exercise. In 
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contrast to apoptotic EMPs, these EVs might contribute to angiogenesis and 
the improvement of endothelial function under exercise conditions. 
4.2.3 Immune signaling during exercise mediated by EVs? 
An interesting finding from the surface marker analysis is the neat increase of 
EVs derived from leukocytes, including lymphocytes, monocytes and antigen 
presenting cells, during and immediately after exercise. EV Array as well as 
MACSPlex analysis detected several markers for T cells (CD4, CD8), 
monocytes (CD14), and AP cells (MHCII) on ExerVs (fig. 3.19 and 3.25). 
Increasing levels of cytokines and leukocytes in response to exercise reflect 
the induction of an inflammatory process during physical activity (Nielsen et 
al., 2016; Pedersen et al., 2000). However, the in vivo influence of exercise on 
immune cell release of EVs is rarely examined. Sossdorf et al. also found 
CD14+ monocytic MPs elevated immediately and 45 min after 90 min of cycling 
exercise (80 % of IAT) (Sossdorf et al., 2011). Chaar et al. found MVs derived 
from neutrophils (CD15+MP) elevated in response to three consecutive bouts 
of exercise (Chaar et al., 2011). The detection of immune-cell derived EVs 
under exercise conditions might indicate their contribution to immune signaling 
processes. EVs are considered important immune-modulatory vehicles which 
efficiently transfer antigens and immune-stimulatory signals (Robbins et al., 
2014; Tkach et al., 2017). Likewise, muscle-derived EVs are believed to 
transport myokines (=cytokines released by muscle cells) to recipient tissues 
in response to exercise stimuli (Piccirillo, 2019; Whitham et al., 2018). 
Therefore, ExerVs may enable a directed transport of pro- or anti-inflammatory 
cargo to recipient cells of the circulatory system and the underlying tissues 
during and after exercise. Exercise is considered an anti-inflammatory stimulus 
in different diseases like rheumatic diseases or cancer (Benatti et al., 2015; 
Hojman, 2017). Analysis of the effects of ExerVs on target cells, e.g. in vitro 
on primary muscle cells, or in vivo in mice models of inflammatory diseases, 
may shed light on their contribution to beneficial immune adaptations. 
Furthermore, the assessment of ExerV release in patients suffering from 
inflammatory diseases, such as systemic lupus erythematosus, will further 
define their role in inflammatory signaling. 
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4.3 Limitations of the analysis of ExerVs 
The isolation and characterization of ExerVs from blood plasma is struggled 
by EV heterogeneity, the co-isolation of non-EV components, and insufficient 
specificity of downstream analysis methods. 
4.3.1 Estimation of ExerV concentration is hampered 
Non-EV components in plasma and isolated EVs highly affected the total count 
of ExerVs measured with NTA or imaging flow cytometry. Though NTA 
identified the same EV-rich SEC-fractions as WB analysis (fig. 3.1 and fig. 3.2), 
and NTA of the pooled SEC-EVs (#4-6) revealed a typical size distribution for 
small EVs (fig. 3.3), the more than two-fold increase in EV numbers estimated 
semi-quantitatively by WB in this study (fig. 3.18, 3.20) or comparable EV 
elevations described in the literature (Frühbeis et al., 2015; Guescini et al., 
2015; Whitham et al., 2018) were not measurable. In contrast to this, NTA 
suggested constant EV numbers in response to physical exercise (fig. 3.15 
and 3.16). IF of BODIPY-stained EVs indicated a low increase in EV numbers 
during, but a decrease to baseline concentration immediately post exercise 
when analyzing EVs in plasma (fig. 3.14). Additionally, the intake of a high-fat 
meal had an enormous effect on particle numbers estimated by NTA which 
were elevated by an order of magnitude under postprandial conditions 
(Brahmer et al., 2019). Impaired WB analysis confirmed, that these elevated 
numbers were not due to EV increases in response to food-intake, but rather 
indicated an increased co-isolation of lipoprotein subclasses (chylomicrons). 
Similar findings were described by Sodar et al. who showed that flow 
cytometric analysis of MVs was highly confounded by food-intake (Sodar et 
al., 2016). Though Jamaly et al. did not observe similar effects of food intake 
on NTA of ultracentrifuged plasma EVs, they revealed that 66 % of the 
variation of EV particle numbers were dependent on VLDL concentration in the 
corresponding plasma samples (Jamaly et al., 2018). These findings indicate 
that EV enumeration using NTA and IF conducted under the presented 
conditions is highly susceptible to lipoprotein contamination of EV samples and 
both methods do not measure EVs without vesicle-specific labeling. However, 
IF analysis of single SEC fractions (fig. 3.16) demonstrates that also the choice 
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of membrane dye is of high importance for EV number calculation. Intriguingly, 
the highest numbers of EVs stained by BODIPY were determined in EV-
poor/protein-high fractions estimated by WB (#7-10, fig. 3.2). Conclusively, the 
membrane dye seems to rather label lipoproteins or other non-EV plasma 
components than EVs. This was also recently demonstrated by de Rond et al. 
who compared five generic EV markers in flow cytometric analysis of isolated 
EVs and plasma-EVs (de Rond et al., 2018). Each of the tested markers failed 
to enable measurement of all EVs in the sample or additionally stained non-
EV sample components. In further studies, an appropriate EV staining 
approach should be identified, which would enable correct ExerV enumeration. 
For example, SEC-EVs could be stained with an antibody for CD63 coupled to 
a fluorophore and measured in IF or fluorescent-NTA. Further isolation of EVs, 
e.g. involving antibodies for EV-associated marker proteins followed by 
detachment of the antibodies, could be used. This would also enable to 
measure EV subclasses in a given EV sample. Furthermore, multiple 
innovative EV isolation and characterization methods, which include flow field-
flow fractionation (Sitar et al., 2015) and acoustic approaches (Lee et al., 2015; 
Rezeli et al., 2016), were recently developed. In addition, the invention of 
proper EV reference material has gained increasing attention (Lozano-Andres 
et al., 2019; Valkonen et al., 2017). These developments may provide the 
possibility to estimate actual ExerV concentrations in future experiments. 
Importantly, the calculation of EV numbers should be verified by (immuno-) EM 
imaging although it is time consuming and laborious (Thery et al., 2018; van 
der Pol et al., 2014). In conclusion, the estimation of ExerV numbers was 
impaired by non-EV plasma components during the conducted study, but 
several modifications of the downstream analysis strategy may enable 
calculation of ExerV numbers in future experiments. This will provide a 
profound basis to study the release kinetics of the various ExerV subclasses 
which might also function as minimal-invasive prognostic and diagnostic 
markers. 
4.3.2 Multiplexed assays are confounded by a complex plasma composition 
EV Array technology measuring unpurified EVs in plasma, similarly, was highly 
susceptible to be impaired by plasma components. Characterization of ExerV 
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kinetics needed modification of data evaluation (see chapter 2.5.6) to resolve 
ExerV changes in the background noise resulting from plasma. Adjusted 
evaluation allowed estimation of the kinetics of few markers but most of the 
markers were below detection threshold though detectable in WB and 
MACSPlex (e.g. CD9, CD63, CD81, and CD41, fig. 3.19). This finding 
indicates that non-EV components in plasma might block the epitopes for EV-
capture on the microarray device. Immuno-capture based removal of 
lipoproteins or plasma proteins from the samples prior to measurement in 
EV Array analysis might improve EV Array characterization of ExerVs. 
However, Mork et al. demonstrated that separation of apolipoprotein B from 
plasma samples via anti-apolipoprotein B coated beads was accompanied by 
loss of 21 % of the EV signal in EV Array analysis (Mork et al., 2017). Further 
improvements in the sample preparation and analysis are needed to increase 
the sensitivity of EV Array technology. This may finally enable the resolution of 
the longitudinal changes of markers associated with ExerVs also by EV Array 
technology. 
In the MACSPlex assay, the advantage of analyzing multiple cellular proteins 
in a heterogeneous pool of EVs is accompanied by possible over- or under-
representation of some of the included markers. The data obtained from semi-
quantitative analysis enabled estimation of the ExerV releasing cell 
populations (see chapter 3.4.3). However, antibody competition during EV-
isolation, -capture and -detection in the MACSPlex analyzing process may 
lead to a bias in enrichment of signals for EV carrying epitopes for rather strong 
antibodies. Likewise, excess of EVs originating from a certain cell type (which 
carry one specific marker) may cover the effect of rather underrepresented EV 
species. Koliha et al. introduced the principle of MACSPlex technology and 
specified that the kit is designed to minimize antibody competition but cannot 
be excluded (Koliha et al., 2016). In addition, the linear range of the detection 
system may hamper exact estimation of ExerV dynamics. For example, high 
signal intensities were measured for e.g. CD29, CD42a and HLA-DRDPDQ 
irrespective of exercise status while CD4 and CD14 mostly were only 
detectable at the post exercise level (fig. 3.22). It is possible that fold changes 
of specific markers measured at the upper or lower limit of detection are 
divergent when measured in the appropriate EV concentration. Conclusively, 
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analyses should be performed in dilution series to obtain more detailed 
information about ExerV kinetics. This was also suggested by Wiklander et al. 
who evaluated the MACSPlex approach for different sample materials in more 
detail (Wiklander et al., 2018). Taken together, MACSPlex marker analysis 
constitutes an easy and quick tool to provide profound knowledge on the origin 
of ExerVs. However, precise assay design including EV isolation, choice of 
capture- and detection-antibody as well as utilization of different sample 
dilutions is obligatory. 
4.3.3 Optimization of high-purity ExerV preparation is essential for further 
downstream characterization 
To specifically address putative functions of ExerVs, the estimation of ExerV 
cargo is crucial. However, to apply more sensitive downstream analyses of 
ExerVs, like proteomic analysis or RNA-seq, the purification strategy needs to 
be further improved. Exemplified for one subject, LC-MS proteomic 
characterization of SEC-EVs revealed a high contamination of plasma proteins 
and lipoproteins impairing the detection of EV-specific proteomic content 
(fig. 3.4). Since RNA species can also be associated to co-isolated non-EV 
components e.g. HDL (Vickers et al., 2011), RNA-seq is expected to be 
impaired likewise (Jeppesen et al., 2019). With the aim to increase the purity 
of ExerV samples, a combined purification approach as well as modification of 
IA capture was conducted and evaluated. Density gradient centrifugation 
following SEC enabled the detection of CD81 protein which was not detectable 
in LC-MS of SEC samples before (fig. 3.10). Though, the purity of EVs was still 
poor. Technical reasons cannot be excluded (see chapter 3.1.3) and repetition 
of the isolation approach with improved IDG fraction collection may lead to 
higher-purity EVs. A comparable purification strategy was recently described 
by Karimi et al. who combined EV enrichment on a density cushion with SEC 
(Karimi et al., 2018). This approach led to a reduction of excessive lipoprotein 
co-isolation and enabled detailed proteomic as well as RNA analysis of the 
obtained vesicle fractions. Also, Jeppesen et al. could markedly increase purity 
of small EVs by combining density gradient centrifugation with UC or IA 
capture (Jeppesen et al., 2019). Still, these combined isolation approaches are 
highly laborious and increased sample input is needed. However, this may not 
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be feasible for routine EV analysis. Alternatively, the use of immuno-captured 
EVs can result in sufficiently pure EVs from reduced sample material, if 
isolation antibodies as well as magnetic beads can be removed from the 
samples. The modification of the elution protocol of CD63+ExerVs resulted in 
higher concentrated EV samples and CD81 as well as Syntenin were 
detectable in LC-MS (fig. 3.8). However, this approach also did not lead to 
separation of high plasma protein and lipoprotein background impairing EV 
proteome analysis. Further optimization of the isolation approach, like further 
washing steps and variation of the EV lysis buffer, may increase the purity of 
EVs. Taken together, as already discussed (see chapter 4.3.1), ExerV 
recovery from plasma needs further improvements in quality and feasibility, 
which will enable proper evaluation of proteomic and RNA cargo in future 
studies. 
4.3.4 The comparison of different ExerV studies is limited  
The described challenges highlight the difficulty to compare ExerV study 
results, which comprise a collection of multiple different EV isolation methods 
and characterization strategies. In the present literature on small EVs or 
exosome-called EVs in exercise settings, low-speed centrifugation (Whitham 
et al., 2018), UC (Chaturvedi et al., 2015; Frühbeis et al., 2015; Guescini et al., 
2015), commercial precipitation (Bei et al., 2017; Bertoldi et al., 2018; Oliveira 
et al., 2018), SEC (Brahmer et al., 2019; Lovett et al., 2018), as well as 
acoustic trapping (Bryl-Gorecka et al., 2018) were used to study EVs from 
human, mouse and rat plasma or serum. Importantly, these studies 
consistently found an increasing amount of EVs during or after acute or chronic 
exercise interventions. However, especially the analysis of proteomic and 
nucleic acid content is highly critical since high purity of ExerV populations is 
not provided in the indicated studies. Furthermore, biodistribution and 
functional analysis of isolated ExerVs may be highly influenced by co-isolated 
bioactive material. Encouragingly, the field of extracellular vesicle research is 
developing rapidly, and improved purification and analysis methods may 
enable comparable parallel analysis of ExerVs in the future. 
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5 Conclusion and future perspectives 
The results of the present study strongly indicate a contribution of EV release 
by platelets, leukocytes and endothelial cells to a heterogenous pool of 
ExerVs, in a load-response related fashion. This finding provides a profound 
basis to create working hypotheses to study the putative functions of ExerVs 
in immediate signaling processes like coagulation, immune signaling and 
angiogenesis. Further steps to perform this research include the optimization 
of the technical workflows, identification of the triggers of ExerV formation and 
finally the elucidation of the functional properties of ExerVs. 
First, to overcome the methodical challenges in ExerV characterization, 
improved EV isolation strategies are necessary, which reduce co-isolation of 
non-EV material and results in high-purity ExerVs are necessary. These will 
provide a more detailed analysis of the proteomic, metabolomic and nucleic 
acid content in defined ExerV subpopulations. Furthermore, standardized EV-
isolation and –characterization techniques are required, which enable high-
throughput analysis of ExerVs in controlled trials. At the minute, the 
combination of density gradient centrifugation and size exclusion 
chromatography is one of the most promising approaches to get pure sample 
material. This laborious and time consuming workflow is not feasible for high 
throughput examinations. Magnetic bead isolations are relevant isolation 
technique enabling a straight forward and time saving isolation procedure. 
Additionally, antibody based capturing allows the isolation of highly specific EV 
subclasses. Imaging flow cytometry, which allows the analysis of ExerVs on a 
single EV level could be a promising approach for counting, characterization 
and isolation of EV populations in the future. Methodical refinements of the 
listed and future techniques will allow deeper research on ExerV formation and 
functions.  
Secondly, to further study the nature of ExerV release, variations in the 
exercise setting, analysis of recovery time points, as well as the inclusion of 
different subject cohorts will be versatile. Implementation of interval training 
bouts, endurance and resistance exercise settings as well as several weeks of 
exercise intervention will address time- and load-responsiveness of ExerV 
release. Furthermore, different subject cohorts may reveal additional 
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information on differences in ExerV release, which was already recorded in 
this study regarding low- and high-responders. Relevant study designs may 
include the comparison of trained versus untrained persons, young versus old 
persons, and healthy persons versus patients suffering from diseases such as 
the autoimmune disease systemic lupus erythematosus or cardiovascular 
diseases. Variations in the amount and composition of ExerV populations will 
shed light on the triggers and mechanisms of ExerV formation and release. 
Thirdly, the functions of ExerVs or certain ExerV subclasses can be assessed. 
Comparison of proteomic and nucleic acid analyses of ExerVs with EVs 
obtained at rest and after a recovery time allows the identification of ExerV 
cargo. This may support and further define the contribution of ExerVs to the 
suggested signaling pathways angiogenesis, coagulation and immune 
regulation. Subsequently, the validation of the putative functions of ExerVs and 
their possible involvement in long-term adaptation processes to regular 
physical exercise can be addressed. Experimental approaches will include cell 
culture models of EV release as well as uptake by and effects on different 
target cells, which are involved in endothelial function, coagulation processes 
and immune regulation. Further steps include the identification of target cells 
and tissues in biodistribution assays. Subsequently, the analysis of the 
functional effects of administered ExerVs can be studied in vivo in animal 
exercise models, e.g. involving obese or elderly mice. Animal knock-out 
models which interfere with EV formation, release and/or trafficking in certain 
cellular populations, e.g. endothelial cells or the lymphoid lineage, are needed 
to validate the discovered physiological properties.  
Finally, these analyses will uncover a possible contribution of ExerVs to the 
maintenance of whole-body homeostasis after exercise stimuli, which leads to 
long-term adaptations, and may provide possibilities for their use in prevention, 
diagnostics and treatment of diseases. 
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7 Appendix 
7.1 Supplementary data 
 
Figure S1: Nanoparticle tracking analysis of single SEC fractions. Screenshots 
taken from the videos of the NTA measurements of individual SEC fractions number 
(#)1 to 10 of separated plasma samples. Individual sample dilution is PBS is indicated.  
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Figure S2: Individual data of EV Array marker profiles – values corresponding to 
fig. 3.19 a 
 
 
Figure S3: Individual data of significantly elevated markers in EV Array analysis 
– values corresponding to fig. 3.19 b 
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Table S1: Accumulation of EV data from multiple characterization approaches 
involving 21 subjects. 
 
unpurified 
EVs 
CD9+EVs CD63+EVs CD81+EVs SEC-EVs 
S* 
EV 
Array 
IF WB MPlx WB MPlx WB MPlx IF NTA WB MPlx 
1 X X       X    
2 X X           
3 X  X X X X X X     
4 X         X X X 
5 X         X X X 
6 X         X X  
7 X         X X  
8 X            
9 X         X X  
10 X         X X  
13   X X X X X X     
14       X X   X X 
15     X X X X   X X 
16       X X   X X 
17       X X  X X X 
18           X X 
19     X X      X 
21      X  X     
22   X X X X X X     
23   X X X X X X     
24    X        X 
∑ 10 2 4 5 6 7 8 9 1 7 11 9 
IF Imaging flow cytometry, MPlx MACSPlex, WB western blotting, NTA nanoparticle 
tracking analysis; *The blood of S11, S12, and S20 was not used for the analysis of 
EVs in the scope of this thesis. Numbering is consistent to prevent misunderstanding. 
 
Table S2: Statistical analysis of EV Array marker changes 
marker level 
fold 
change 
CI upper CI lower 
Bonferroni-Holm 
corrected 
post hoc p-value 
Alix post 1.17 1.30 1.04 0.02086 
Alix RQ 0.9 1.07 1.20 0.95 0.49669 
CD14 post 1.22 1.44 1.04 0.03200 
CD14 RQ 0.9 1.03 1.21 0.88 1.33387 
CD142 post 1.15 1.24 1.07 0.00369 
CD142 RQ 0.9 1.11 1.19 1.03 0.02222 
HLA-ABC post 1.35 1.65 1.10 0.01888 
HLA-ABC RQ 0.9 1.24 1.49 1.03 0.05271 
ICAM-1 post 1.22 1.41 1.06 0.02678 
ICAM-1 RQ 0.9 1.13 1.31 0.98 0.15612 
LAMP-1 post 1.21 1.31 1.12 0.00052 
LAMP-1 RQ 0.9 1.10 1.19 1.02 0.03614 
tPA post 1.19 1.37 1.03 0.03691 
tPA RQ 0.9 0.99 0.85 1.15 1.76157 
CI confidence interval 
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Table S3: Statistical analysis of WB marker changes 
marker level 
EV 
subclass 
fold 
change 
CI 
upper 
CI  
lower 
Bonferroni-Holm 
corrected 
post hoc p-value 
CD9 post CD63+EVs 1.88 2.75 1.28 0.01171 
CD9 RQ 0.9 CD63+EVs 1.45 2.20 0.96 0.14503 
CD9 post CD81+EVs 1.79 2.15 1.49 0.00007 
CD9 RQ 0.9 CD81+EVs 1.23 1.48 1.02 0.06189 
CD9 post SEC-EVs 2.56 3.92 1.68 0.00034 
CD9 RQ 0.9 SEC-EVs 1.44 2.23 0.93 0.19283 
CD41b post CD81+EVs 8.65 15.04 4.97 0.00001 
CD41b RQ 0.9 CD81+EVs 2.88 5.01 1.66 0.00331 
CD41b post SEC-EVs 2.44 3.74 1.59 0.00058 
CD41b RQ 0.9 SEC-EVs 1.52 2.36 0.97 0.12737 
CD63 post CD81+EVs 1.93 2.74 1.36 0.00289 
CD63 RQ 0.9 CD81+EVs 1.59 2.26 1.12 0.02643 
CD63 post SEC-EVs 1.91 2.53 1.44 0.00026 
CD63 RQ 0.9 SEC-EVs 1.29 1.72 0.96 0.17247 
CD81 post SEC-EVs 2.15 3.18 1.45 0.00168 
CD81 RQ 0.9 SEC-EVs 1.53 2.30 1.02 0.08305 
CI confidence interval 
 
Table S4: Statistical analysis of MACSPlex marker changes 
marker level 
EV 
subclass 
fold 
change 
CI 
upper 
CI 
lower 
Bonferroni-Holm 
corrected 
post hoc p-value 
CD4 post SEC-EVs 4.40 7.52 2.58 0.00014 
CD4 RQ 0.9 SEC-EVs 1.35 2.38 0.77 0.79570 
CD4 post CD9+EVs 7.45 19.01 2.92 0.00773 
CD4 RQ 0.9 CD9+EVs 1.78 5.05 0.63 0.65701 
CD4 post CD81+EVs 9.56 20.76 4.40 0.00006 
CD4 RQ 0.9 CD81+EVs 1.63 3.54 0.75 0.59156 
CD4 post CD63+EVs 10.40 20.57 5.26 0.00008 
CD4 RQ 0.9 CD63+EVs 1.36 2.83 0.66 1.08704 
CD8 post CD9+EVs 1.72 2.27 1.31 0.00657 
CD8 RQ 0.9 CD9+EVs 1.20 1.61 0.89 0.60064 
CD8 post SEC-EVs 1.33 1.56 1.13 0.00596 
CD8 RQ 0.9 SEC-EVs 1.14 1.36 0.96 0.38817 
CD8 post CD81+EVs 1.80 2.36 1.36 0.00134 
CD8 RQ 0.9 CD81+EVs 1.14 1.51 0.87 0.94466 
CD8 post CD63+EVs 1.41 1.75 1.13 0.01600 
CD8 RQ 0.9 CD63+EVs 1.18 1.49 0.94 0.40177 
CD9 post SEC-EVs 1.64 2.41 1.11 0.04808 
CD9 RQ 0.9 SEC-EVs 1.30 1.99 0.85 0.61414 
CD9 post CD81+EVs 2.53 3.48 1.84 0.00004 
CD9 RQ 0.9 CD81+EVs 1.25 1.72 0.91 0.47621 
CD9 post CD63+EVs 1.97 3.07 1.26 0.02004 
CD9 RQ 0.9 CD63+EVs 1.01 1.62 0.63 2.87174 
CD14 post CD63+EVs 7.57 14.13 4.06 0.00035 
CD14 RQ 0.9 CD63+EVs 2.31 4.55 1.17 0.06732 
CD14 post CD81+EVs 7.08 19.50 2.57 0.00363 
CD14 RQ 0.9 CD81+EVs 1.96 5.41 0.71 0.51793 
CD14 post SEC-EVs 5.47 17.09 1.75 0.03665 
CD14 RQ 0.9 SEC-EVs 1.67 5.97 0.47 1.04739 
CD24 post CD81+EVs 2.06 2.65 1.60 0.00005 
CD24 RQ 0.9 CD81+EVs 1.17 1.51 0.91 0.59153 
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CD24 post CD63+EVs 1.79 2.26 1.42 0.00060 
CD24 RQ 0.9 CD63+EVs 1.15 1.48 0.90 0.71901 
CD24 post CD9+EVs 1.89 2.79 1.28 0.01793 
CD24 RQ 0.9 CD9+EVs 1.20 1.82 0.78 1.05016 
CD29 post CD81+EVs 1.85 2.58 1.32 0.00375 
CD29 RQ 0.9 CD81+EVs 1.03 1.43 0.74 2.60916 
CD29 post CD63+EVs 2.30 3.63 1.45 0.00630 
CD29 RQ 0.9 CD63+EVs 1.20 1.95 0.74 1.29742 
CD29 post SEC-EVs 1.81 2.62 1.24 0.01321 
CD29 RQ 0.9 SEC-EVs 1.43 2.15 0.95 0.25664 
CD31 post CD81+EVs 2.52 3.80 1.67 0.00063 
CD31 RQ 0.9 CD81+EVs 1.28 1.93 0.85 0.67087 
CD31 post CD63+EVs 3.73 8.11 1.71 0.01003 
CD31 RQ 0.9 CD63+EVs 1.31 2.98 0.57 1.46190 
CD40 post CD63+EVs 2.35 4.20 1.32 0.02573 
CD40 RQ 0.9 CD63+EVs 1.03 1.90 0.55 2.79085 
CD40 post CD81+EVs 2.92 6.24 1.36 0.02627 
CD40 RQ 0.9 CD81+EVs 1.63 3.49 0.76 0.57468 
CD40 post CD9+EVs 2.62 4.14 1.66 0.00467 
CD40 RQ 0.9 CD9+EVs 1.57 2.58 0.96 0.20667 
CD41b post CD81+EVs 1.96 2.75 1.40 0.00194 
CD41b RQ 0.9 CD81+EVs 1.41 1.98 1.00 0.14183 
CD41b post CD63+EVs 1.75 2.60 1.18 0.02829 
CD41b RQ 0.9 CD63+EVs 1.07 1.62 0.70 2.22711 
CD41b post SEC-EVs 1.61 2.35 1.11 0.04967 
CD41b RQ 0.9 SEC-EVs 1.35 2.03 0.89 0.43423 
CD42a post CD81+EVs 2.20 3.40 1.42 0.00428 
CD42a RQ 0.9 CD81+EVs 1.25 1.92 0.81 0.89606 
CD42a post CD63+EVs 2.27 3.46 1.49 0.00389 
CD42a RQ 0.9 CD63+EVs 1.49 2.33 0.95 0.22821 
CD42a post SEC-EVs 1.60 2.21 1.16 0.02123 
CD42a RQ 0.9 SEC-EVs 1.31 1.87 0.92 0.35623 
CD44 post CD81+EVs 2.10 3.23 1.36 0.00729 
CD44 RQ 0.9 CD81+EVs 1.28 1.97 0.83 0.70822 
CD44 post SEC-EVs 1.74 2.59 1.17 0.03235 
CD44 RQ 0.9 SEC-EVs 1.22 1.85 0.80 0.99274 
CD44 post CD63+EVs 3.40 5.90 1.96 0.00071 
CD44 RQ 0.10 CD63+EVs 1.21 2.18 0.67 0.48582 
CD44 post CD9+EVs 10.46 85.53 1.28 0.03352 
CD44 RQ 0.10 CD9+EVs 2.64 25.82 0.27 0.34803 
CD45 post CD81+EVs 2.88 4.72 1.75 0.00128 
CD45 RQ 0.9 CD81+EVs 1.25 2.04 0.76 1.06361 
CD45 post CD63+EVs 3.21 7.04 1.47 0.02904 
CD45 RQ 0.9 CD63+EVs 1.37 3.22 0.58 1.23898 
CD49e post CD81+EVs 3.19 5.41 1.88 0.00080 
CD49e RQ 0.9 CD81+EVs 1.50 2.55 0.89 0.36460 
CD49e post CD9+EVs 2.61 4.10 1.66 0.00449 
CD49e RQ 0.9 CD9+EVs 0.97 0.59 1.58 2.62917 
CD49e post CD63+EVs 2.50 4.72 1.32 0.02740 
CD49e RQ 0.9 CD63+EVs 1.21 2.38 0.62 1.63533 
CD62P post CD9+EVs 2.64 3.81 1.82 0.00130 
CD62P RQ 0.9 CD9+EVs 1.97 2.94 1.32 0.01515 
CD62P post SEC-EVs 1.71 2.27 1.29 0.00339 
CD62P RQ 0.9 SEC-EVs 1.53 2.09 1.12 0.03339 
CD62P post CD81+EVs 2.91 5.24 1.62 0.00426 
CD62P RQ 0.9 CD81+EVs 1.61 2.90 0.90 0.31323 
CD62P post CD63+EVs 2.56 5.14 1.27 0.03874 
CD62P RQ 0.9 CD63+EVs 1.25 2.61 0.60 1.58205 
CD63 post CD81+EVs 2.45 3.20 1.88 0.00001 
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CD63 RQ 0.9 CD81+EVs 1.26 1.64 0.97 0.24630 
CD63 post SEC-EVs 1.52 1.95 1.19 0.00770 
CD63 RQ 0.9 SEC-EVs 1.11 1.45 0.84 1.30058 
CD69 post CD63+EVs 2.38 4.37 1.30 0.02748 
CD69 RQ 0.9 CD63+EVs 1.31 2.50 0.69 1.10546 
CD69 post SEC-EVs 1.68 2.35 1.20 0.01602 
CD69 RQ 0.9 SEC-EVs 1.25 1.82 0.86 0.64237 
CD81 post CD63+EVs 1.45 1.76 1.19 0.00450 
CD81 RQ 0.9 CD63+EVs 1.16 1.43 0.94 0.42393 
CD105 post CD81+EVs 4.33 5.77 3.25 0.00000 
CD105 RQ 0.9 CD81+EVs 1.44 1.92 1.08 0.04613 
CD105 post CD9+EVs 3.67 5.61 2.40 0.00052 
CD105 RQ 0.9 CD9+EVs 1.41 2.24 0.89 0.36254 
CD105 post CD63+EVs 3.20 5.07 2.03 0.00082 
CD105 RQ 0.9 CD63+EVs 1.23 2.01 0.75 1.10742 
CD105 post SEC-EVs 2.27 3.62 1.42 0.00903 
CD105 RQ 0.9 SEC-EVs 1.39 2.37 0.82 0.58232 
CD146 post CD81+EVs 3.29 4.99 2.17 0.00005 
CD146 RQ 0.9 CD81+EVs 1.35 2.05 0.89 0.42985 
CD146 post CD63+EVs 3.48 5.29 2.29 0.00012 
CD146 RQ 0.9 CD63+EVs 1.18 1.84 0.76 1.28799 
CD146 post CD9+EVs 2.40 3.65 1.57 0.00530 
CD146 RQ 0.9 CD9+EVs 1.33 2.10 0.84 0.55934 
CD146 post SEC-EVs 2.00 2.97 1.34 0.00693 
CD146 RQ 0.9 SEC-EVs 1.36 2.07 0.90 0.39927 
HLA-ABC post CD81+EVs 2.90 4.00 2.10 0.00001 
HLA-ABC RQ 0.9 CD81+EVs 1.34 1.84 0.97 0.22208 
HLA-ABC post CD63+EVs 2.65 3.74 1.88 0.00018 
HLA-ABC RQ 0.9 CD63+EVs 1.46 2.10 1.01 0.13129 
HLA-ABC post CD9+EVs 2.69 3.66 1.97 0.00039 
HLA-ABC RQ 0.9 CD9+EVs 1.39 1.94 0.99 0.16857 
HLA-DRDPDQ post CD81+EVs 3.42 4.84 2.42 0.00000 
HLA-DRDPDQ RQ 0.9 CD81+EVs 1.41 1.99 1.00 0.15654 
HLA-DRDPDQ post CD63+EVs 2.87 3.71 2.21 0.00001 
HLA-DRDPDQ RQ 0.9 CD63+EVs 1.23 1.62 0.94 0.36426 
HLA-DRDPDQ post CD9+EVs 2.25 3.13 1.62 0.00191 
HLA-DRDPDQ RQ 0.9 CD9+EVs 1.13 1.62 0.79 1.32814 
HLA-DRDPDQ post SEC-EVs 1.68 2.41 1.17 0.02369 
HLA-DRDPDQ RQ 0.9 SEC-EVs 1.14 1.69 0.77 1.48009 
CI confidence interval 
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